<SEC-DOCUMENT>0001104659-24-037418.txt : 20240322
<SEC-HEADER>0001104659-24-037418.hdr.sgml : 20240322
<ACCEPTANCE-DATETIME>20240321182036
ACCESSION NUMBER:		0001104659-24-037418
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20240322
DATE AS OF CHANGE:		20240321

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Annovis Bio, Inc.
		CENTRAL INDEX KEY:			0001477845
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				262540421
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-276814
		FILM NUMBER:		24772603

	BUSINESS ADDRESS:	
		STREET 1:		101 LINDENWOOD DRIVE, SUITE 225
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355
		BUSINESS PHONE:		484-875-3192

	MAIL ADDRESS:	
		STREET 1:		101 LINDENWOOD DRIVE, SUITE 225
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	QR Pharma, Inc.
		DATE OF NAME CHANGE:	20091202
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>tm248202d5_424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Filed pursuant to Rule 424(b)(5)</B></P>

<P STYLE="margin: 0; text-align: right"><B>Registration No. 333-276814</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>PROSPECTUS SUPPLEMENT</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20">(To
Prospectus dated February&nbsp;12, 2024)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<IMG SRC="tm248202d5_424b5img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><B>316,455 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We are offering
316,455 shares (the &ldquo;Shares&rdquo;) of our common stock, $0.0001 par value per share (the &ldquo;Common Stock&rdquo;) in a registered
direct offering to an institutional investor (the &ldquo;Investor&rdquo;) pursuant to this prospectus supplement and the accompanying
prospectus. We are not using a placement agent for this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">The Shares have been registered
pursuant to an effective shelf registration statement on Form&nbsp;S-3 (File No.&nbsp;333-276814), which was declared effective on February&nbsp;12,
2024. The Shares are being offered pursuant to this prospectus supplement and the accompanying prospectus. For a more detailed description
of the Shares, see the section entitled &ldquo;Description of Our Common Stock&rdquo; beginning on page&nbsp;S-17. No placement agent
is involved in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">Our Common Stock
trades on the NYSE under the symbol &ldquo;ANVS.&rdquo; On March 20, 2024, the last closing price of our Common Stock as reported on NYSE
was $11.10 per share. The offering price for each share of Common Stock is $9.48 which was the five-day average closing price preceding
the execution of the securities purchase agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20"><B>Investing in our Common Stock
involves risks. Please read &ldquo;Risk Factors&rdquo; beginning on page&nbsp;S-6 of this prospectus supplement and in the related sections
in the accompanying prospectus and in the documents incorporated herein by reference.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #231f20; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #231f20; text-align: center; border-bottom: Black 1pt solid">Per Share</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #231f20; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #231f20; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 74%; color: #231f20">Offering Price</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">9.48</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">3,000,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">Proceeds, before expenses, to us</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">9.48</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">3,000,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">Net proceeds from the sale of
the Shares will be used for working capital and general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">Pursuant to the terms of the Purchase
Agreement, the Company has agreed to certain restrictions on future stock offerings, including that during the 30-day period following
March&nbsp;22, 2024, the Company will not (i)&nbsp;issue (or enter into any agreement to issue) any shares of common stock or common stock
equivalents, subject to certain exceptions, or (ii)&nbsp;file any registration statement or any amendment or supplement thereto relating
to the offering or resale of any shares of the Company or any securities convertible into or exercisable or exchangeable for shares of
Company, subject to certain exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20"><B>Investing in our securities
involves a high degree of risk. You should purchase our securities only if you can afford a complete loss of your investment. See &ldquo;Risk
Factors&rdquo; beginning on page&nbsp;S-6 of this prospectus supplement and on page&nbsp;5 of the accompanying prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20"><B>Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or
accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We expect that delivery of the
Shares being offered pursuant to this prospectus supplement and the accompanying prospectus will be made on or about March&nbsp;22, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B>The date of this prospectus
supplement is March&nbsp;21, 2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B>Prospectus Supplement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96%; text-align: right"></TD>
    <TD STYLE="width: 4%; text-align: right"><B><U>Page</U></B></TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT
    THIS PROSPECTUS SUPPLEMENT</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></A></TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAUTIONARY NOTE REGARDING
    FORWARD LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_002">S-2</A></TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS SUPPLEMENT SUMMARY</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-3</FONT></A></TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE OFFERING</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-5</FONT></A></TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_005">S-6</A></TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_006">S-13</A></TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIVIDEND POLICY</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_007">S-14</A></TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAPITALIZATION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_008">S-15</A></TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DILUTION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_009">S-16</A></TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_010">DESCRIPTION OF OUR COMMON STOCK</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_010">S-17</A></TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_011">S-18</A></TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_012">S-19</A></TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_013">S-19</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_014">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_014">S-20</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_015">WHERE YOU CAN FIND MORE INFORMATION</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_015">S-21</A></TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prospectus</B></FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: right"></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Page</U></B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#m_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#m_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></A></TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#m_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#m_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></A></TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#m_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE COMPANY</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#m_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></A></TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#m_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#m_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></A></TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#m_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#m_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></A></TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#m_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GENERAL DESCRIPTION OF OUR SECURITIES</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#m_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></A></TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#m_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF OUR CAPITAL STOCK</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#m_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></A></TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#sp04_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF DEBT SECURITIES</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp04_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></A></TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#sp04_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF OUR WARRANTS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp04_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></A></TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#sp04_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF OUR UNITS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp04_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></A></TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#sp04_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp04_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></A></TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#sp04_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp04_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></A></TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#sp04_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#sp04_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></A></TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#sp04_007">WHERE YOU CAN FIND ADDITIONAL INFORMATION; INCORPORATION BY REFERENCE</A></FONT><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#sp04_007">24</A></FONT></TD>
    </TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20"><B>You should rely only on the
information contained in this prospectus supplement and the accompanying prospectus. We have not authorized anyone else to provide you
with additional or different information. We are offering to sell, and seeking offers to buy, our securities only in jurisdictions where
offers and sales are permitted. You should not assume that the information in this prospectus supplement or the accompanying prospectus
is accurate as of any date other than the date on the front of those documents or that any document incorporated by reference is accurate
as of any date other than its filing date.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20"><B>No action is being taken in
any jurisdiction outside the United States to permit a public offering of our securities or possession or distribution of this prospectus
supplement or the accompanying prospectus in that jurisdiction. Persons who come into possession of this prospectus supplement or the
accompanying prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions
as to this offering and the distribution of this prospectus supplement and the accompanying prospectus applicable to that jurisdiction.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></FONT></P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><A NAME="a_001"></A><B>ABOUT THIS PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">On February&nbsp;1, 2024, we filed
with the SEC a registration statement on Form&nbsp;S-3 (File No.&nbsp;333-252801), utilizing a shelf registration process relating to
the securities described in this prospectus supplement, which registration statement was declared effective on February&nbsp;12, 2024.
Under this shelf registration process, we may, from time to time, sell up to $250 million in the aggregate of shares of Common Stock,
shares of preferred stock, debt securities, warrants and units. Following this offering, there will be approximately $246 million of securities
remaining available for sale under the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">This document is in two parts.
The first part is this prospectus supplement, which describes the specific terms of this offering and also adds to and updates information
contained in the accompanying prospectus and the documents incorporated by reference into the prospectus. The second part, the accompanying
prospectus, gives more general information, some of which does not apply to this offering. You should read this entire prospectus supplement
as well as the accompanying prospectus and the documents incorporated by reference that are described under &ldquo;Where You Can Find
More Information&rdquo; in this prospectus supplement and the accompanying prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">If the description of the offering
varies between this prospectus supplement and the accompanying prospectus, you should rely on the information contained in this prospectus
supplement. However, if any statement in one of these documents is inconsistent with a statement in another document having a later date
 &mdash; for example, a document incorporated by reference in this prospectus supplement and the accompanying prospectus &mdash; the statement
in the document having the later date modifies or supersedes the earlier statement. Except as specifically stated, we are not incorporating
by reference any information submitted under Item 2.02 or Item 7.01 of any Current Report on Form&nbsp;8-K into any filing under the Securities
Act or the Securities Exchange Act of 1934, as amended, or the Exchange Act, into this prospectus supplement or the accompanying prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">Any statement contained in a document
incorporated by reference, or deemed to be incorporated by reference, into this prospectus supplement or the accompanying prospectus will
be deemed to be modified or superseded for purposes of this prospectus supplement or the accompanying prospectus to the extent that a
statement contained herein, therein or in any other subsequently filed document which also is incorporated by reference in this prospectus
supplement or the accompanying prospectus modifies or supersedes that statement. Any such statement so modified or superseded will not
be deemed, except as so modified or superseded, to constitute a part of this prospectus supplement or the accompanying prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We further note that the representations,
warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in
this prospectus supplement and the accompanying prospectus were made solely for the benefit of the parties to such agreement, including,
in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation,
warranty or covenant to you unless you are a party to such agreement. Moreover, such representations, warranties or covenants were accurate
only as of the date when made or expressly referenced therein. Accordingly, such representations, warranties and covenants should not
be relied on as accurately representing the current state of our affairs unless you are a party to such agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">Unless we have indicated otherwise,
or the context otherwise requires, references in this prospectus supplement and the accompanying prospectus to &ldquo;Annovis,&rdquo;
the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo; and &ldquo;our&rdquo; or similar terms refer to refer to Annovis Bio,&nbsp;Inc.,
a Delaware corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><A NAME="a_002"></A><B>CAUTIONARY NOTE REGARDING FORWARD
LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">This prospectus supplement, the
accompanying prospectus and the documents we have filed with the SEC that are incorporated herein by reference contain forward-looking
statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) and Section&nbsp;21E
of the Exchange Act. Forward-looking statements deal with our current plans, intentions, beliefs and expectations and statements of future
economic performance. Statements containing terms such as &ldquo;believe,&rdquo; &ldquo;do not believe,&rdquo; &ldquo;plan,&rdquo; &ldquo;expect,&rdquo;
 &ldquo;intend,&rdquo; &ldquo;estimate,&rdquo; &ldquo;anticipate&rdquo; and other phrases of similar meaning are considered to contain
uncertainty and are forward-looking statements. In addition, from time to time we or our representatives have made or will make forward-looking
statements orally or in writing. Furthermore, such forward-looking statements may be included in various filings that we make with the
SEC, or press releases or oral statements made by or with the approval of one of our authorized executive officers. These forward- looking
statements are subject to certain known and unknown risks and uncertainties, as well as assumptions that could cause actual results to
differ materially from those reflected in these forward-looking statements. Factors that might cause actual results to differ include,
but are not limited to, those set forth under &ldquo;Risk Factors&rdquo; incorporated by reference in this prospectus supplement and those
discussed in Item 7, &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operation,&rdquo; in our
Annual Report on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923040275/anvs-20221231x10k.htm" STYLE="-sec-extract: exhibit">Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2022</A> and in our future filings made with the SEC. Readers
are cautioned not to place undue reliance on any forward-looking statements contained in this prospectus supplement, the accompanying
prospectus or the documents we have filed with the SEC that are incorporated herein by reference, which reflect management&rsquo;s opinions
only as of their respective dates. Except as required by law, we undertake no obligation to revise or publicly release the results of
any revisions to any forward-looking statements. You are advised, however, to consult any additional disclosures we have made or will
make in our reports to the SEC on Forms 10-K, 10-Q and 8-K. All subsequent written and oral forward-looking statements attributable to
us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained in this prospectus,
any prospectus supplement or any related issuer free writing prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<DIV STYLE="padding: 10pt; border: Black 1pt solid">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><A NAME="a_003"></A>&nbsp;<B>PROSPECTUS SUPPLEMENT SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">The following summary highlights
selected information contained or incorporated by reference in this prospectus supplement. This summary does not contain all of the information
you should consider before investing in the securities. Before making an investment decision, you should read the entire prospectus and
any supplement hereto carefully, including the risk factors section as well as the financial statements and the notes to the financial
statements incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: #231f20"><B>Our Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical stage, drug platform company addressing neurodegeneration, such as Alzheimer&rsquo;s disease (&ldquo;AD&rdquo;) and Parkinson&rsquo;s
disease (&ldquo;PD&rdquo;). We are developing our lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially
other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant
compound. In several studies, Buntanetap was observed to inhibit the synthesis of neurotoxic proteins &mdash; APP/A</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&beta;
</FONT>(&ldquo;APP&rdquo;), tau/phospho- tau (&ldquo;tau&rdquo;) and <FONT STYLE="font-family: Times New Roman, Times, Serif">&alpha;</FONT>-Synuclein
(&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">&alpha;</FONT>SYN&rdquo;) &mdash; that are one of the main causes of
neurodegeneration. High levels of neurotoxic proteins lead to impaired axonal transport, which is responsible for the communication between
and within nerve cells. When that communication is impaired, the immune system is activated and attacks the nerve cells, eventually killing
them. We have observed in our clinical studies in early AD and early PD patients and pre-clinical studies in mice and rats that Buntanetap
lowered neurotoxic protein levels leading to improved axonal transport, reduced inflammation, lower nerve cell death and improved affected
function.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">In 2021, we completed two Phase
1/2 clinical studies: one in 14 early AD patients, and one in 54 early PD patients (together, the &ldquo;AD/PD Trials&rdquo;). In the
AD/PD Trials, early AD patients were defined as those with a Mini Mental State Examination (MMSE) score between 19 and 28 and early PD
patients as those patients at Hoehn&nbsp;&amp; Yahr stages 1, 2 or 3. MMSE is a brief screening instrument used to assess cognitive function,
with total scores ranging from 0 to 30 and a lower score indicating greater disease severity, while the Hoehn&nbsp;&amp; Yahr scale is
a medical assessment used to measure staging of the functional disability associated with PD where a higher stage indicates greater disease
severity. In collaboration with the Alzheimer&rsquo;s Disease Cooperative Study (&ldquo;ADCS&rdquo;), we also conducted a trial in 16
early AD patients (the &ldquo;ADCS Trial&rdquo;). In the ADCS Trial, early AD patients were defined as those patients with a MMSE score
between 19 and 28. All three clinical trials were double-blind, placebo-controlled studies. We designed the studies by applying our understanding
of the underlying neurodegenerative disease states, and measured both target and pathway validation in the spinal fluid of patients to
determine whether patients improved following treatment. In addition to meeting their primary endpoints of safety and tolerability and
secondary endpoint of pharmacokinetics of Buntanetap, our AD/PD Trials met exploratory endpoints of measures of biomarkers and improvements
in cognition in AD patients, and in function in PD patients. We believe that the AD/PD Trials represent the first double-blind placebo-controlled
studies that showed improvements in AD patients, as measured by ADAS-Cog, and in PD patients, as measured by UPDRS. Following completion
of the AD/PD Trials, we submitted our data to the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) and requested direction to further
pursue the development of Buntanetap in early PD patients. With the FDA&rsquo;s guidance, we initiated a Phase 3 study in early PD patients
in August&nbsp;2022 (our &ldquo;Phase 3 PD Study&rdquo;). In the Phase 3 PD Study, early PD patients were defined as those at Hoehn&nbsp;&amp;
Yahr stages 1, 2 or 3 and OFF times of less than two hours per day. OFF time refers to when PD motor and/or non-motor symptoms occur between
medication doses. We also submitted a proposed protocol for the treatment of moderate AD to the FDA, and after receiving permission to
proceed, we initiated a Phase 2/3 study in mild to moderate AD patients in February&nbsp;2023 (our &ldquo;Phase 2/3 AD Study&rdquo;).
In the Phase 2/3 AD Study, mild to moderate AD patients were defined as those with a MMSE score between 14 and 24. At the completion of
the ADCS Trial, the data showed that Buntanetap is a translational inhibitor in humans just like in animals, and we further observed that
there was statistical improvement in cognition in early AD patients, just like in the AD/PD Trials.</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 10pt; border: Black 1pt solid">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">Our Phase 3 PD Study and
Phase 2/3 AD Study each have built in interim analyses. Our Phase 3 PD Study incorporated an interim analysis at two months, the
results of which were disclosed on March&nbsp;31, 2023. The pre-planned interim analysis was conducted by our data analytics
provider based on 132 patients from all cohorts collectively for which baseline and two-month data was available. As the interim
analysis was conducted at two months of the six-month endpoint and only on 132 patients, it may not be indicative of the results at
six months for the full patient population because as the trial progresses, clinical outcomes may materially change as patient
enrollment continues and more patient data become available, or different conclusions or considerations may qualify such results
once additional data have been received and fully evaluated. Based on the results of the interim analysis, we proceeded with the
Phase 3 PD Study as planned in accordance with the previously established protocol. The study was completed on December&nbsp;4,
2023, and we have been organizing and cleaning data since that date. We remain blinded to the Phase 3 PD Study and we do not have
safety or efficacy data from the trial, yet. We disclosed the results of the interim analysis for our Phase 2/3 AD Study on
October&nbsp;23, 2023, and as for the PD study based on the outcome of the interim analysis we proceeded with the study as planned.
The Phase 2/3 AD study was completed on February&nbsp;13, 2024. Again, as for the PD study we are organizing and cleaning the data,
while we are still blinded to all data. We plan to consult with the FDA following completion of the full analyses of the two
studies, to obtain feedback on our planned AD and PD studies, including conducting disease-modifying studies and open label
extensions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">By the end of 2026, our goal is
to have conducted the required pivotal studies for Buntanetap to be able to file two new drug applications (&ldquo;NDAs&rdquo;) with the
FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that we are the only company developing a drug for AD and PD that is designed to inhibit more than one neurotoxic protein,
and has a mechanism of action designed to restore nerve cell axonal and synaptic activity. By improving brain function, our goal is
to treat memory loss and dementia associated with AD as well as body and brain function associated with PD. Based on pre-clinical
and clinical data collected to date, we believe that Buntanetap has the potential to be the first drug to interfere with the
underlying mechanism of neurodegeneration, potentially enabling Buntanetap to be the only drug to improve cognition in AD and motor
function in PD. The industry has encountered challenges in specifically targeting one neurotoxic protein, be it APP, tau or </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&alpha;</FONT>SYN,
indicating that doing so does not change the course of neurodegeneration. Our goal is to develop a disease modifying drug
(&ldquo;DMD&rdquo;) for patients with neurodegeneration by leveraging our clinical and pre-clinical data to inhibit the three most
relevant neurotoxic proteins. Studies have found that AD and PD are the most common neurodegenerative diseases in the U.S., and
accordingly these diseases present two unmet needs of the aging population and two potentially large U.S. markets if a DMD is
developed and approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We have never been profitable
and have incurred net losses since inception. Our Accumulated deficit at December&nbsp;31, 2023 was $111,185,592 (unaudited). We expect
to incur losses for the foreseeable future, and we expect these losses to increase as we continue our development of, and seek regulatory
approvals for, our product candidates. Because of the numerous risks and uncertainties associated with product development, we are unable
to predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated in Delaware in 2008. Our principal executive offices are located at 101 Lindenwood Drive, Suite&nbsp;225, Malvern, PA
19355 and our telephone number is (484) 875-3192. Our website address is </FONT>www.annovisbio.com. The inclusion of our website address
is, in each case, intended to be an inactive textual reference only and not an active hyperlink to our website. The information contained
in, or that can be accessed through, our website is not part of this prospectus.</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="text-align: center; padding: 10pt; border: Black 1pt solid">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><A NAME="a_004"></A>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20"><B>Issuer:</B></FONT></TD>
    <TD STYLE="width: 55%"><FONT STYLE="font-size: 10pt">Annovis Bio,&nbsp;Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20"><B>Shares of Common Stock offered by
    us pursuant to this prospectus supplement:</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20">316,455 shares</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20"><B>Shares of Common Stock outstanding
    prior to this offering:</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">10,694,844 shares</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20"><B>Shares of Common Stock to be outstanding
    immediately after this offering:</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20">11,011,299 shares</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20"><B>Use of proceeds:</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">We intend to use the net proceeds from the sale of securities in this offering for working capital
    and other general corporate purposes. See &ldquo;Use of Proceeds&rdquo; on page&nbsp;S-13 of this prospectus supplement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20"><B>Transfer agent and registrar:</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20"><B>Risk factors:</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Investing in our securities involves a high degree of risk. For a discussion of factors you should
    consider carefully before deciding to invest in our shares of Common Stock, see the information contained in or incorporated by reference
    under the heading &ldquo;Risk Factors&rdquo; beginning on page&nbsp;S-6 of this prospectus supplement, on page&nbsp;5 of the accompanying
    prospectus, and in the other documents incorporated by reference into this prospectus supplement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20"><B>NYSE symbol:</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20">ANVS</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B><A NAME="a_005"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20"><I>Before you make a decision
to invest in our securities, you should consider carefully the risks described below, together with other information in this prospectus
supplement, the accompanying prospectus and the information incorporated by reference herein and therein. If any of the following events
actually occur, our business, operating results, prospects or financial condition could be materially and adversely affected. This could
cause the trading price of our Common Stock to decline and you may lose all or part of your investment. The risks described below are
not the only ones that we face. Additional risks not presently known to us or that we currently deem immaterial may also significantly
impair our business operations and could result in a complete loss of your investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B>RISKS RELATED TO THIS OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>Since our management will have broad discretion
in how we use the proceeds from this offering, we may use the proceeds in ways with which you disagree.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We have not allocated specific
amounts of the net proceeds from this offering for any specific purpose. Accordingly, our management will have significant flexibility
in applying the net proceeds of this offering. You will be relying on the judgment of our management with regard to the use of these net
proceeds, and you will not have the opportunity, as part of your investment decision, to influence how the proceeds are being used. It
is possible that the net proceeds will be invested in a way that does not yield a favorable, or any, return for us. The failure of our
management to use such funds effectively could have a material adverse effect on our business, financial condition, operating results
and cash flow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>You will experience immediate and substantial dilution
in the net tangible book value per share of the Common Stock you purchase.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">Since the offering price per share
of Common Stock being offered is substantially higher than the net tangible book value per share of our Common Stock, you will suffer
substantial dilution in the net tangible book value of the Common Stock you purchase in this offering. Based on the offering price of
$9.48 per share of Common Stock, if you purchase shares of Common Stock in this offering, you will suffer immediate and substantial dilution
of $9.92 per share in the net tangible book value of the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>Because we are a small company, the requirements
of being a public company, including compliance with the reporting requirements of the Securities Exchange Act of 1934, as amended (the
 &ldquo;Exchange Act&rdquo;), and the requirements of the Sarbanes-Oxley Act and the Dodd-Frank Act, may strain our resources, increase
our costs and distract management, and we may be unable to comply with these requirements in a timely or cost-effective manner.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">As a public company with listed
equity securities, we must comply with the federal securities laws, rules&nbsp;and regulations, including certain corporate governance
provisions of the Sarbanes-Oxley Act of 2002 (the &ldquo;Sarbanes-Oxley Act&rdquo;) and the Dodd-Frank Act, related rules&nbsp;and regulations
of the SEC and the NYSE, with which a private company is not required to comply. Complying with these laws, rules&nbsp;and regulations
occupies a significant amount of the time of our Board of Directors and management and significantly increases our costs and expenses.
Among other things, we must:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Symbol"></FONT></TD><TD>maintain a system of internal control over financial reporting in compliance with the requirements of Section&nbsp;404 of the Sarbanes-Oxley
Act and the related rules&nbsp;and regulations of the SEC and the Public Company Accounting Oversight Board;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>comply with rules&nbsp;and regulations promulgated by the exchange;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>prepare and distribute periodic public reports in compliance with our obligations under the federal securities laws;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>maintain various internal compliance and disclosures policies, such as those relating to disclosure controls and procedures and insider
trading in our Common Stock;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>involve and retain to a greater degree outside counsel and accountants in the above activities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>maintain a comprehensive internal audit function; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>maintain an investor relations function.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>Future sales of our Common Stock, whether by us
or our shareholders, could cause our stock price to decline.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">If our existing stockholders
sell, or indicate an intent to sell, substantial amounts of our Common Stock in the public market, the trading price of our Common
Stock could decline significantly. Similarly, the perception in the public market that our stockholders might sell shares of our
Common Stock could also depress the market price of our Common Stock. A decline in the price of shares of our Common Stock might
impede our ability to raise capital through the issuance of additional shares of our Common Stock or other equity securities. In
addition, the issuance and sale by us of additional shares of our Common Stock or securities convertible into or exercisable for
shares of our Common Stock, or the perception that we will issue such securities, could reduce the trading price for our Common
Stock as well as make future sales of equity securities by us less attractive or not feasible. The sale of shares of Common Stock
issued upon the exercise of our outstanding options and warrants could further dilute the holdings of our then existing
shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>Securities analysts may not cover our Common Stock
and this may have a negative impact on the market price of our Common Stock.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">The trading market for our
Common Stock will depend, in part, on the research and reports that securities or industry analysts publish about us or our
business. We do not have any control over independent analysts (provided that we have engaged various non-independent analysts). We
do not currently have and may never obtain research coverage by independent securities and industry analysts. If no independent
securities or industry analysts commence coverage of us, the trading price for our Common Stock would be negatively impacted. If we
obtain independent securities or industry analyst coverage and if one or more of the analysts who covers us downgrades our Common
Stock, changes their opinion of our shares or publishes inaccurate or unfavorable research about our business, our stock price would
likely decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, demand for our
Common Stock could decrease and we could lose visibility in the financial markets, which could cause our stock price and trading
volume to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>You may experience future dilution as a result of
future equity offerings or other equity issuances.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We may in the future issue
additional shares of our Common Stock or other securities convertible into or exchangeable for shares of our Common Stock. We cannot
assure you that we will be able to sell shares of our Common Stock or other securities in any other offering or other transactions
at a price per share that is equal to or greater than the price per share paid by Investors in this offering. The price per share at
which we sell additional shares of our Common Stock or other securities convertible into or exchangeable for our Common Stock in
future transactions may be higher or lower than the price per share in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>The price of our Common Stock may be volatile or
may decline, which may make it difficult for investors to resell shares of our Common Stock at prices they find attractive.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">The trading price of our Common
Stock may fluctuate widely as a result of a number of factors, many of which are outside our control. In addition, the stock market is
subject to fluctuations in the share prices and trading volumes that affect the market prices of the shares of many companies. These broad
market fluctuations could adversely affect the market price of our Common Stock. Among the factors that could affect our stock price are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>results of our clinical trials, and the results of trials of our competitors or those of other companies in our market sector;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to enroll subjects in our future clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delays or unanticipated developments in the completion of our planned clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any delay in submitting an NDA and any adverse development or perceived adverse development with respect to the FDA&rsquo;s review
of that NDA;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to obtain and maintain regulatory approval of buntanetap or any future product candidates or additional indications thereof,
or limitations to specific label indications or patient populations for its use, or changes or delays in the regulatory review process;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>failure to successfully develop and commercialize buntanetap or any future product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the degree and rate of physician and market adoption of any of our current and future product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>inability to obtain additional funding or obtaining funding on unattractive terms;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>regulatory or legal developments in the United States and other countries applicable to buntanetap or any other product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>adverse regulatory decisions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>changes in the structure of healthcare payment systems;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>manufacturing, supply or distribution delays or shortages, including our inability to obtain adequate product supply for buntanetap
or any other product candidates, or the inability to do so at acceptable prices;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the success or failure of our efforts to identify, develop, acquire or license additional product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>introduction of new products, services or technologies by our competitors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>failure to meet or exceed financial projections we provide to the public;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>failure to meet or exceed the estimates and projections of the investment community;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>changes in the market valuations of companies similar to ours;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>market conditions in the pharmaceutical and biotechnology sectors, and the issuance of new or changed securities analysts&rsquo; reports
or recommendations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any changes to our relationship with any manufacturers, suppliers, collaborators or other strategic partners;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>significant lawsuits, including patent or shareholder litigation, and disputes or other developments relating to our proprietary rights,
including patents, litigation matters and our ability to obtain patent protection for our technologies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>additions or departures of key scientific or management personnel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>sales of our common stock by us or our stockholders in the future;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>changes in our capital structure, such as future issuances of securities and the incurrence of additional debt;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>changes in accounting standards, policies, guidelines, interpretations or principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>trading volume of our Common Stock;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>actual or anticipated fluctuations in our financial condition and results of operations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>publication of news releases by other companies in our industry, and especially direct competitors, including about adverse developments
related to safety, effectiveness, accuracy and usability of their products, reputational concerns, reimbursement coverage, regulatory
compliance, and product recalls;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>progression of geopolitical events (including in relation to the conflict between Russia and Ukraine); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the other factors described in this &ldquo;Risk Factors&rdquo; section, in the accompanying Prospectus or in any document incorporated
by reference herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">The stock market has experienced
significant volatility recently. As a result, the market price of our Common Stock may be volatile. In addition, the trading volume in
our Common Stock may fluctuate more than usual and cause significant price variations to occur. The trading price of the shares of our
Common Stock and the value of our other securities will depend on many factors, which may change from time to time, including, without
limitation, our financial condition, performance, creditworthiness and prospects, future sales of our equity or equity related securities,
and other factors identified below in &ldquo;Forward-Looking Statements.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">Accordingly, the shares of
our Common Stock that an investor purchases, whether in this offering or in the secondary market, may trade at a price lower than
that at which they were purchased, and, similarly, the value of our other securities may decline. Current levels of market
volatility are unprecedented. The capital and credit markets have been experiencing volatility and disruption for more than a year.
In some cases, the markets have produced downward pressure on stock prices and credit availability for certain issuers without
regard to those issuers&rsquo; underlying financial strength.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">A
significant decline in our stock price could result in substantial losses for individual stockholders and could lead to costly and disruptive
securities litigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>There is an increased risk associated with an investment
in our Common Stock.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We have not attained profitable
operations and are dependent upon obtaining financing to continue operations for the next twelve months from the date of these financial
statements. Our future is dependent upon our ability to obtain financing or upon future profitable operations. We reserve the right to
seek additional funds through public/private placements of our Common Stock and/or through debt financing. Our ability to raise additional
financing is unknown. For these reasons, management had disclosed in our financial statements, and our auditors have stated an explanatory
paragraph in their report that there is substantial doubt we will be able to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>Our failure to meet the New York Stock Exchange&rsquo;s
continued listing requirements could result in a delisting of our Common Stock.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">If we fail to satisfy the continued
listing requirements of the New York Stock Exchange, such as the corporate governance requirements or the minimum closing bid price requirement,
the New York Stock Exchange may take steps to delist our Common Stock. Such a delisting would likely have a negative effect on the price
of our Common Stock and would impair our stockholders&rsquo; ability to sell or purchase our Common Stock when they wish to do so. In
the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would
allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, or prevent future
non-compliance with the listing requirements of the New York Stock Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>We have been subject to securities class action
litigation in the past, and could be subject to such litigation in the future.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">In the past, securities class
action litigation has often been brought against companies following a decline in the market price of their securities. This risk is especially
relevant for us because biotechnology companies have experienced significant share price volatility in recent years. During the year ended
December&nbsp;31, 2021, two securities class action complaints were filed against us and our executive officers following disclosure of
interim results from the AD/PD Trials. Both complaints were voluntarily dismissed without prejudice by the plaintiffs. If we again face
such litigation in the future, it could result in substantial costs, a diversion of management&rsquo;s attention and resources, and damage
to our reputation, which could have a material adverse effect on our business, financial condition and results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>Our directors, executive officers and certain shareholders
will continue to own a significant percentage of our common stock and, if they choose to act together, will be able to exert significant
control over matters subject to stockholder approval.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">Our
directors, executive officers, and stockholders affiliated with our directors and executive officers will own 25.6% of the current
voting power of our outstanding Common Stock. Therefore, acting together, they have the ability to substantially influence all
matters submitted to our stockholders for approval. For example, these holders may be able to control the appointment of our
management, elections and removal of directors, amendments of our organizational documents, or approval of any merger, sale of
assets, or other major corporate transaction. The interests of these holders may not always coincide with our corporate interests or
the interests of other stockholders, and they may act in a manner with which our stockholders may not agree or that may not be in
the best interests of our other stockholders. This concentration of ownership may have the effect of delaying, deferring or
preventing a change in control, impeding a merger, consolidation, takeover or other business combination involving us, or
discouraging a potential acquiror from making a tender offer or otherwise attempting to obtain control of our business, even if such
a transaction would benefit other stockholders. So long as they continue to own a significant amount of our equity, these holders
will be able to strongly influence or effectively control our decisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>Our warrants are accounted for as a warrant liability
and were recorded at fair value upon issuance with any changes in fair value each period reported in earnings, which may have an adverse
effect on the market price of our securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We issued 1,250,000 warrants in
November&nbsp;2023 which are accounted for as liabilities, which means that we recorded them at fair value upon issuance with any changes
in fair value each period reported in earnings as determined by us based upon a valuation report obtained from an independent third party
valuation firm. We initially recorded a warrant liability of $13.7 million and recognized an expense amounting to $11.8 million during
the year ended December&nbsp;31, 2023. The impact of future changes in fair value on earnings may also have an adverse effect on the market
price of our securities, including as a result of increased volatility in our earnings due to fluctuations in the value of the warrants
as well as increased costs associated with obtaining such valuations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>We identified a material weakness in our internal
control over financial reporting, which resulted in the restatement of our financial statements for several prior quarterly and year-to-date
periods. If remediation of this material weakness is not effective, or if we fail to maintain an effective system of internal control
over financial reporting in the future, we may not be able to accurately or timely report our financial condition or operating results,
which may adversely affect investor confidence in our company and, as a result, the value of our Common Stock.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We identified a material weakness
in our internal control over financial reporting as of February&nbsp;23, 2023. As defined in the standards established by the U.S. Public
Company Accounting Oversight Board, a &ldquo;material weakness&rdquo; is a deficiency, or combination of deficiencies, in internal control
over financial reporting, such that there is a reasonable possibility that a material misstatement of our company&rsquo;s annual or interim
financial statements will not be prevented, or detected on a timely basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">The material weakness identified
related to the proper classification of research and development expenses, which impacted our previously issued condensed financial statements
as of and for the three months ended March&nbsp;31, 2022, three and six months ended June&nbsp;30, 2022 and three and nine months ended
September&nbsp;30, 2022. As further described in note 12 to our financial statements included in our Annual Report on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923040275/anvs-20221231x10k.htm" STYLE="-sec-extract: exhibit">Form&nbsp;10-K for the fiscal year ended December&nbsp;31 2022</A> which is incorporated by reference in this prospectus supplement, there were material amounts
inappropriately classified as research and development expense which should have been classified as prepaid assets and other assets. We
are taking steps to remediate the material weakness and are in the process of supplementing our existing internal controls related to
the proper classification of research and development expenses. In response to the material weakness, we are enhancing our review procedures
over significant contracts with contract manufacturing organizations and contract research organizations, augmenting existing staff and
strengthening our review process. The incremental internal controls created to respond to this material weakness are being integrated
into our internal controls testing plan and are being tested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">Although we plan to complete
the above remediation process and associated evaluation and testing as quickly as possible, we may not be able to do so and our
initiatives may prove not to be successful. If our remedial measures are insufficient to address the material weakness, or if
additional material weaknesses or significant deficiencies in our internal control over financial reporting are discovered during
the evaluation and testing process, we will be unable to assert that our internal control over financial reporting is effective and
our independent registered public accounting firm will be unable to express an opinion on the effectiveness of our internal control.
If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our
financial results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting,
which would harm our business and the trading price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>We are an &ldquo;emerging growth company,&rdquo;
and the reduced reporting requirements applicable to emerging growth companies may make our common stock less attractive to investors.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We are an &ldquo;emerging
growth company,&rdquo; as defined in the Jumpstart Our Business Startups Act (&ldquo;JOBS Act&rdquo;). For as long as we continue to
be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other
public companies that are not emerging growth companies, including exemption from compliance with the auditor attestation
requirements of Section&nbsp;404, reduced disclosure obligations regarding executive compensation and exemptions from the
requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute
payments not previously approved. We will remain an emerging growth company until the earlier of (1)&nbsp;the last day of the fiscal
year (a)&nbsp;following the fifth anniversary of the closing of our initial public offering (&ldquo;IPO&rdquo;) on January&nbsp;31,
2020, (b)&nbsp;in which we have total annual gross revenue of at least $1.235 billion or (c)&nbsp;in which we are deemed to be a
large accelerated filer, which means the market value of our common stock held by non-affiliates equals or exceeds $700 million as
of the end of our prior second fiscal quarter, and (2)&nbsp;the date on which we have issued more than $1.0 billion in
non-convertible debt during the prior three-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">In addition, under the JOBS Act,
emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies.
We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will
be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We cannot predict if investors
will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive
as a result, there may be a less active trading market for our common stock and our share price may be more volatile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>Provisions in our restated certificate of incorporation
and amended and restated bylaws and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders,
more difficult and may prevent attempts by our stockholders to replace or remove our current management.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">Provisions in our restated certificate
of incorporation and our amended and restated bylaws that became effective upon the closing of our IPO may discourage, delay or prevent
a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which
our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might
be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition,
because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent
any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members
of our board of directors. Among other things, these provisions include those establishing advance notice bylaw provisions for proposals
from stockholders for presentation at annual meetings and forum selection bylaw provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>Because we are incorporated in Delaware, we are
governed by the provisions of Section&nbsp;203 of the General Corporation Law of the State of Delaware, which prohibits a person who owns
in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction
in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed
manner.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">Furthermore, our restated
certificate of incorporation that became effective upon the closing of our IPO specifies that, unless we consent in writing to the
selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most
legal actions involving actions brought against us by stockholders. We believe this provision benefits us by providing increased
consistency in the application of Delaware law by chancellors particularly experienced in resolving corporate disputes, efficient
administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum
litigation. However, the provision may have the effect of discouraging lawsuits against our directors and officers. The
enforceability of similar choice of forum provisions in other companies&rsquo; certificates of incorporation has been challenged in
legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the
choice of forum provisions contained in our restated certificate of incorporation to be inapplicable or unenforceable in such
action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>Our bylaws designate the Court of Chancery of the
State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders,
which could limit our stockholders&rsquo; ability to obtain a favorable judicial forum for disputes with us or our directors, officers
or employees.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">Our bylaws provide that,
unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the
exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders with respect to our company
and our directors. This choice of forum provision may limit a stockholder&rsquo;s ability to bring a claim in a judicial forum that
the stockholder believes is favorable for disputes with us or our directors, which may discourage meritorious claims from being
asserted against us and our directors. Alternatively, if a court were to find this provision of our charter inapplicable to, or
unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated
with resolving such matters in other jurisdictions, which could adversely affect our business, financial condition or results of
operations. We adopted this provision because we believe it makes it less likely that we will be forced to incur the expense of
defending duplicative actions in multiple forums and less likely that plaintiffs&rsquo; attorneys will be able to employ such
litigation to coerce us into otherwise unjustified settlements, and we believe the risk of a court declining to enforce this
provision is remote, as the General Assembly of Delaware has specifically amended the Delaware General Corporation Law to authorize
the adoption of such provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>We have not paid and do not intend to pay dividends
on our Common Stock. Investors in this offering may never obtain a return on their investment.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We have not paid dividends on
our Common Stock inception, and do not intend to pay any dividends on our Common Stock in the foreseeable future. We intend to reinvest
earnings, if any, in the development and expansion of our business. Accordingly, you will need to rely on sales of your shares of Common
Stock after price appreciation, which may never occur, in order to realize a return on your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B><A NAME="a_006"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We estimate that the net proceeds
from this offering will be approximately $2.95 million, after deducting the estimated offering expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We intend to use the net proceeds
from this offering for working capital and other general corporate purposes; provided, however, that none of such proceeds will be used
(a)&nbsp;for the satisfaction of any portion of the Company&rsquo;s debt (other than payment of trade payables in the ordinary course
of the Company&rsquo;s business and prior practices), (b)&nbsp;for the redemption of any Common Stock or Common Stock Equivalents, or
(c)&nbsp;in violation of FCPA or OFAC regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">The amounts and timing of our
use of proceeds will vary depending on a number of factors, including the amount of cash generated or used by our operations, and the
rate of growth, if any, of our business. As a result, we will retain broad discretion in the allocation of the net proceeds of this offering.
In addition, while we have not entered into any agreements, commitments or understandings relating to any significant transaction as of
the date of this prospectus supplement, we may use a portion of the net proceeds to pursue acquisitions, joint ventures and other strategic
transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B><A NAME="a_007"></A>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We have never declared or
paid any cash dividends on our Common Stock. We anticipate that we will retain any earnings to support operations and to finance the
growth and development of our business. Therefore, we do not expect to pay cash dividends in the foreseeable future. Any future
determination relating to our dividend policy will be made at the discretion of our board of directors and will depend on a number
of factors, including future earnings, capital requirements, financial conditions and future prospects and other factors the board
of directors may deem relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B><A NAME="a_008"></A>CAPITALIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; color: #231f20">The following table sets forth our capitalization
as of December&nbsp;31, 2023:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="width: 95%">on an actual basis; and</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>on an as adjusted basis to give effect to (i)&nbsp;the issuance and sale of 316,455 shares of Common Stock, after deducting estimated
offering expenses payable by us.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">As of December&nbsp;31, 2023</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Actual</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">As adjusted</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="font-size: 1pt; vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; font-size: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; font-size: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">(Unaudited)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font-size: 10pt; padding-bottom: 1pt">Cash</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,754,720</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">9,629,720</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left; padding-bottom: 1pt">Prepaid and other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">3,690,662</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">3,690,662</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left; padding-bottom: 1pt">Total Assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">9,445,382</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">13,320,382</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left; padding-bottom: 1pt">Accounts Payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">1,292,837</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">1,292,837</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left; padding-bottom: 1pt">Accrued Expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">3,149,896</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">3,149,896</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left; padding-bottom: 1pt">Total Current Liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">4,442,733</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">4,442,733</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left; padding-bottom: 1pt">Warrant Liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">13,680,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">13,680,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left; padding-bottom: 1pt">Total Liabilities </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">18,122,733</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">18,122,733</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">Shareholders&rsquo; equity:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">Common stock, $0.0001 par value, 70,000,000 shares authorized, 10,519,933 shares issued and outstanding at December&nbsp;31, 2023, and 11,011,299 shares outstanding, as adjusted, respectively</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">1,052</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">1,101</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">Additional Paid in Capital</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">102,507,189</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">106,382,140</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left; padding-bottom: 1pt">Accumulated Deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">(111,185,592</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">(111,185,592</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left; padding-bottom: 1pt">Total shareholders&rsquo; equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">(8,677,351</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">(4,802,351</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left; padding-bottom: 2.5pt">Total capitalization</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">9,445,382</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231f20; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: right">13,320,382</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; color: #231f20; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">The number of issued and outstanding
shares as of December&nbsp;31, 2023 in the table above excludes, as of such date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>1,954,774 shares of Common Stock that were issuable upon exercise of stock options of the exercise of stock options outstanding as
of December&nbsp;30, 2023;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>1,200,000 shares reserved for Common Stock warrants that were issued on November&nbsp;2, 2023, pursuant to an Underwriting Agreement
with Canaccord Genuity LLC., having an exercise price of $9.00 per share;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>35,545 shares reserved for future issuance of equity awards under the Company&rsquo;s 2019 Equity Incentive Plan as of December&nbsp;31,
2023; and</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>2,400 shares of common stock issuable upon the exercise of outstanding warrants having an exercise price of $7.50 per share.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">The as adjusted
in the table above includes, as of such date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 51.95pt">$925,000 of net proceeds from Common Stock issued to an institutional investor in a registered direct
offering on March 19, 2024</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="padding-right: 51.95pt">&nbsp;</TD></TR>
                                    </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 51.95pt">114,911 shares of Common Stock that were issued to an institutional investor in a registered direct
offering on March 19, 2024</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: #231f20"><B><A NAME="a_009"></A>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">If you invest in our Shares in
this offering, your interest will be diluted immediately to the extent of the difference between the offering price per share of the Shares
you will pay in this offering and the as adjusted net tangible book value per share of our Common Stock after giving effect to this offering.
Our historical net tangible book value as of December&nbsp;31, 2023 was $(8,677,351), or $(0.83) per share of Common Stock. Historical
net tangible book value per share represents the amount of our total tangible assets less total liabilities, divided by the number of
shares of our Common Stock outstanding on December&nbsp;31, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">After giving effect to the assumed
sale of the Shares at an assumed offering price of $9.48 per share, and after deducting estimated expenses payable by us, our net tangible
book value as of December&nbsp;31, 2023 would have been approximately $(4,802,351), or $(0.44) per share. This represents an immediate
increase in as adjusted net tangible book value per share of $0.39 to existing stockholders and immediate dilution in net tangible book
value of $9.92 per share to the Investors participating in this offering. The following table illustrates this per share dilution to the
Investors participating in this offering:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 75%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20">Offering price per share</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20">9.48</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20">Net
    tangible book value per share as of December&nbsp;31, 2023</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20">(0.83</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20">)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase attributable to new investors</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20">0.39</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As adjusted net tangible book value per share after this offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.44</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20">Dilution per share to new investors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231F20">9.92</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">The above discussion and table
are based on 10,519,933 shares of our Common Stock outstanding as of December&nbsp;31, 2023 and excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>1,954,774 shares of Common Stock that were issuable upon exercise of stock options of the exercise of stock options outstanding as
of December&nbsp;31, 2023;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>1,200,000 shares reserved for Common Stock warrants that were issued on November&nbsp;2, 2023, pursuant to an Underwriting Agreement
with Canaccord Genuity LLC.;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>35,545 shares reserved for future issuance of equity awards under the Company&rsquo;s 2019 Equity Incentive Plan as of December&nbsp;31,
2023; and</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>2,400 shares of common stock issuable upon the exercise of outstanding warrants having an exercise price of $7.50 per share.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">As adjusted
net tangible book value in the table above includes, as of such date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 48.3pt 0pt 48.5pt; text-indent: 19.95pt; color: #231f20">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 51.95pt">$925,000
                                            of net proceeds from Common Stock issued to an institutional investor in a registered direct
                                            offering on March 19, 2024</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="padding-right: 51.95pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 51.95pt">114,911
                                            shares of Common Stock that were issued to an institutional investor in a registered direct
                                            offering on March 19, 2024</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">To the extent that any (i)&nbsp;options
are exercised, (ii)&nbsp;new options are issued under our equity incentive plan, or (iii)&nbsp;we otherwise issue additional shares of
Common Stock in the future at a price less than the offering price, there may be further dilution to new Investors purchasing our securities
in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B><A NAME="a_010"></A>DESCRIPTION OF OUR COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">The material terms of our Common
Stock are described under the heading &ldquo;Description of Our Capital Stock&rdquo; in the accompanying base prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">Equiniti Trust Company, LLC is
the transfer agent and registrar for our Common Stock. Our Common Stock is listed on the New York Stock Exchange under the symbol &ldquo;ANVS.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><A NAME="a_011"></A><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We have entered into a securities
purchase agreement directly with an institutional investor in connection with this offering. We will make offers only to a limited number
of accredited investors. We are not using a placement agent. The offering is expected to close on or about March&nbsp;22, 2024, subject
to customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>No Sales of Similar Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We have agreed, subject to certain
exceptions, not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of, any shares of Common Stock
(or securities convertible into or exercisable for Common Stock) or, subject to certain exceptions, file any registration statement, including
any amendments or supplements thereto (other than the prospectus supplement, registration statement or amendment to the registration statement
relating to the securities offered hereunder and a registration statement on Form&nbsp;S-8), until 30 days after the completion of this
offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">The transfer agent and registrar
for our Common Stock is Equiniti Trust Company, LLC, 48 Wall Street, Floor 23, New York, NY 10005. Our transfer agent&rsquo;s phone number
is (800) 401-1957.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20">Our shares of Common Stock are quoted on the
NYSE under the trading symbol &ldquo;ANVS&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><A NAME="a_012"></A><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">Certain legal matters with respect
to the validity of the offered securities will be passed upon for us by Loeb&nbsp;&amp; Loeb LLP, New York, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B><A NAME="a_013"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">The consolidated financial statements
of our Company appearing in our annual report on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923040275/anvs-20221231x10k.htm" STYLE="-sec-extract: exhibit">Form&nbsp;10-K for the fiscal years ended December&nbsp;31, 2022</A> and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000155837022002668/anvs-20211231x10k.htm" STYLE="-sec-extract: exhibit">2021</A> have been audited
by WithumSmith+Brown, PC, independent registered public accounting firm, as set forth in the reports thereon included therein and incorporated
herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such reports given on
the authority of such firms as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><A NAME="a_014"></A><B>INCORPORATION OF CERTAIN DOCUMENTS
BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">The SEC allows us to
 &ldquo;incorporate by reference&rdquo; into this prospectus supplement the information from other documents that we file with it,
which means that we can disclose important information to you by referring you to those documents. The information we incorporate by
reference is an important part of this prospectus supplement, and later information that we file with the SEC will automatically
update and supersede some of this information. We incorporate by reference the documents listed below and any future filings we make
with the SEC under Section&nbsp;13(a), 13(c), 14 or 15(d)&nbsp;of the Exchange Act, including filings made after the date of the
initial registration statement, until we sell all of the shares covered by this prospectus supplement or the sale of shares by us
pursuant to this prospectus supplement is terminated. In no event, however, will any of the information that we furnish to, pursuant
to Item 2.02 or Item 7.01 of any Current Report on Form&nbsp;8-K (including exhibits related thereto) or other applicable SEC rules,
rather than file with, the SEC be incorporated by reference or otherwise be included herein, unless such information is expressly
incorporated herein by a reference in such furnished Current Report on Form&nbsp;8-K or other furnished document. The documents we
incorporate by reference are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="width: 95%"><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923040275/anvs-20221231x10k.htm" STYLE="-sec-extract: exhibit">our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2022 as filed with the SEC on March&nbsp;31, 2023;</A></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our Quarterly Reports on Form&nbsp;10-Q for the quarters ended March&nbsp;31, 2023, June&nbsp;30, 2023 and September&nbsp;30, 2023,
filed with the SEC on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000155837023009142/anvs-20230331x10q.htm" STYLE="-sec-extract: exhibit">May&nbsp;10, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000155837023014884/anvs-20230630x10q.htm" STYLE="-sec-extract: exhibit">August&nbsp;14, 2023</A> and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000155837023018298/anvs-20230930x10q.htm" STYLE="-sec-extract: exhibit">November&nbsp;8, 2023</A>, respectively;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our Current Reports on Form&nbsp;8-K as filed with the SEC on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923001850/tm232502d1_8k.htm" STYLE="-sec-extract: exhibit">January&nbsp;6, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923019581/tm236582d1_8k.htm" STYLE="-sec-extract: exhibit">February&nbsp;13, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923029078/tm238624d1_8k.htm" STYLE="-sec-extract: exhibit">March&nbsp;6, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923039748/tm2310923d1_8k.htm" STYLE="-sec-extract: exhibit">March&nbsp;31, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923041009/tm2311180d2_8k.htm" STYLE="-sec-extract: exhibit">April&nbsp;3, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923041237/tm2311180d3_8k.htm" STYLE="-sec-extract: exhibit">April&nbsp;4, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923066171/tm2317351d1_8k.htm" STYLE="-sec-extract: exhibit">May&nbsp;30, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923072250/tm2318997d1_8k.htm" STYLE="-sec-extract: exhibit">June&nbsp;16, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923108892/tm2328385d1_8k.htm" STYLE="-sec-extract: exhibit">October&nbsp;13, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923112633/tm2329368d2_8k.htm" STYLE="-sec-extract: exhibit">October&nbsp;30, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923113281/tm2329368d4_8k.htm" STYLE="-sec-extract: exhibit">November&nbsp;1, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465924035082/tm248952d1_8k.htm" STYLE="-sec-extract: exhibit">March&nbsp;15, 2024</A> and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465924036742/tm249369d1_8k.htm" STYLE="-sec-extract: exhibit">March&nbsp;20, 2024</A> (except information included pursuant to Items 2.02 or 7.01 and exhibits related to
such items);</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the information specifically incorporated by reference into our <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923040275/anvs-20221231x10k.htm" STYLE="-sec-extract: exhibit">Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2022</A> from our <A HREF="https://www.sec.gov/Archives/edgar/data/1477845/000110465923052107/tm2312833d3_def14a.htm" STYLE="-sec-extract: exhibit">Definitive Proxy Statement filed with the SEC on April&nbsp;28, 2023</A> (other than the portions thereof that are furnished
and not filed); and</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><A HREF="https://www.sec.gov/Archives/edgar/data/1477845/000110465921140386/tm2133159d1_8a12b.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Symbol">&middot;</FONT></A></TD><TD><A HREF="https://www.sec.gov/Archives/edgar/data/1477845/000110465921140386/tm2133159d1_8a12b.htm" STYLE="-sec-extract: exhibit">the description of our capital stock contained in our Registration Statement on Form&nbsp;8-A filed with the SEC on November&nbsp;17,
2021 and any amendments or supplements thereto.</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">Any statement contained in this
prospectus supplement, the accompanying prospectus or in a document incorporated or deemed to be incorporated by reference into this prospectus
supplement and the accompanying prospectus will be deemed to be modified or superseded for purposes of this prospectus supplement and
the accompanying prospectus to the extent that a statement contained in this prospectus supplement and the accompanying prospectus or
any other subsequently filed document that is deemed to be incorporated by reference into this prospectus supplement and the accompanying
prospectus modifies or supersedes the statement. Any statements so modified or superseded shall not be deemed, except as so modified or
superseded, to constitute a part of this prospectus supplement and the accompanying prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20">You may obtain a copy of these filings, without
charge, by writing or calling us at:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B>Annovis Bio,&nbsp;Inc.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B>101 Lindenwood Drive,</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B>Suite&nbsp;225</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B>Malvern, PA 19355</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: #231f20"><B>Attn: Investor
Relations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">You should rely only on the information
incorporated by reference or provided in this prospectus supplement or the accompanying prospectus. We have not authorized anyone else
to provide you with different information. You should not assume that the information in this prospectus supplement or the accompanying
prospectus is accurate as of any date other than the date on the front page&nbsp;of those documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B><A NAME="a_015"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We have filed a registration statement
with the SEC under the Securities Act with respect to the shares of Common Stock offered by this prospectus supplement. This prospectus
supplement is part of that registration statement and does not contain all the information included in the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">For further information with respect
to our shares of Common Stock and us, you should refer to the registration statement, its exhibits and the material incorporated by reference
therein. Portions of the exhibits have been omitted as permitted by the rules&nbsp;and regulations of the SEC. Statements made in this
prospectus supplement and the accompanying prospectus as to the contents of any contract, agreement or other document referred to are
not necessarily complete. In each instance, we refer you to the copy of the contracts or other documents filed as an exhibit to the registration
statement, and these statements are hereby qualified in their entirety by reference to the contract or document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registration statement may be obtained from the web site that the Securities and Exchange Commission maintains at </FONT>http://www.sec.gov.
We file annual, quarterly and current reports and other information with the SEC. You may read any reports, statements or other information
on file at the SEC&rsquo;s web site at http://www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 3 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm248202d5_424b5sp3img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$250,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock <BR>
Preferred Stock<BR>

Debt Securities<BR>
 Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may offer and sell from time
to time shares of common stock, shares of preferred stock, debt securities, warrants, or any combination of those securities, either individually
or in units, up to an aggregate initial offering price of $250,000,000, in one or more transactions under this prospectus. We may also
offer common stock or preferred stock upon conversion of debt securities, common stock upon conversion of preferred stock, or common stock,
preferred stock, or debt securities upon the exercise of warrants. The securities may be offered in amounts, at prices and on terms to
be determined based on market conditions at the time of sale and set forth in an accompanying prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This prospectus provides you with
a general description of the securities that we may offer. Each time we offer securities, we will provide you with a prospectus supplement
that describes specific information about the particular securities being offered and may add, update or change information contained
or incorporated by reference in this prospectus. You should read both this prospectus and the applicable prospectus supplement, together
with the additional information that is incorporated by reference into this prospectus and the applicable prospectus supplement, before
you invest in any of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The securities may be sold by
us to or through underwriters or dealers, directly to purchasers or through agents designated from time to time, or through a combination
of these methods. For additional information on the methods of sale, you should refer to the section entitled &ldquo;Plan of Distribution&rdquo;
in this prospectus and the comparable section of any applicable prospectus supplement. If any underwriters are involved in the sale of
the securities with respect to which this prospectus is being delivered, the names of such underwriters and any applicable discounts or
commissions and options will be set forth in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our common stock is listed on
the NYSE under the ticker symbol &ldquo;ANVS.&rdquo; On January&nbsp;30, 2024, the last reported sale price per share of our common stock
on the NYSE was $10.75 per share. We have not yet determined whether the other securities that may be offered by this prospectus will
be listed on any exchange, interdealer quotation system or over-the-counter market. If we decide to seek the listing of any such securities
upon issuance, the prospectus supplement relating to those securities will disclose the exchange, quotation system or market on which
those securities will be listed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>INVESTING IN OUR SECURITIES
INVOLVES A HIGH DEGREE OF RISK. RISKS ASSOCIATED WITH AN INVESTMENT IN OUR SECURITIES WILL BE DESCRIBED IN THE APPLICABLE PROSPECTUS SUPPLEMENT
AND CERTAIN OF OUR FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION INCORPORATED BY REFERENCE INTO THIS PROSPECTUS, AS DESCRIBED UNDER
 &ldquo;RISK FACTORS&rdquo; ON PAGE 5.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>You should read this prospectus
and any applicable prospectus supplement together with additional information described under the heading &ldquo;Where You Can Find Additional
Information&rdquo; before you make your investment decision.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Prospectus dated February&nbsp;12,
2024.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>Page</U></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; padding-top: 4pt; width: 90%; text-align: left; padding-bottom: 2pt"><A HREF="#m_001">ABOUT THIS PROSPECTUS</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 4pt; width: 10%; text-align: right; padding-bottom: 2pt"><A HREF="#m_001">1</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2pt"><A HREF="#m_002">FORWARD-LOOKING STATEMENTS</A></TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2pt"><A HREF="#m_002">2</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2pt"><A HREF="#m_003">THE COMPANY</A></TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2pt"><A HREF="#m_003">3</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2pt"><A HREF="#m_004">RISK FACTORS</A></TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2pt"><A HREF="#m_004">5</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"><A HREF="#m_005">USE OF PROCEEDS</A></TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2pt"><A HREF="#m_005">6</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2pt"><A HREF="#m_006">GENERAL DESCRIPTION OF OUR SECURITIES</A></TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2pt"><A HREF="#m_006">7</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2pt"><A HREF="#m_007">DESCRIPTION OF OUR CAPITAL STOCK</A></TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2pt"><A HREF="#m_007">8</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2pt"><A HREF="#sp04_001">DESCRIPTION OF DEBT SECURITIES</A></TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2pt"><A HREF="#sp04_001">12</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2pt"><A HREF="#sp04_002">DESCRIPTION OF OUR WARRANTS</A></TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2pt"><A HREF="#sp04_002">19</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2pt"><A HREF="#sp04_003">DESCRIPTION OF OUR UNITS</A></TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2pt"><A HREF="#sp04_003">20</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"><A HREF="#sp04_004">PLAN OF DISTRIBUTION</A></TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2pt"><A HREF="#sp04_004">21</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2pt"><A HREF="#sp04_005">LEGAL MATTERS</A></TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2pt"><A HREF="#sp04_005">24</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"><A HREF="#sp04_006">EXPERTS</A></TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2pt"><A HREF="#sp04_006">24</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2pt"><A HREF="#sp04_007">WHERE YOU CAN FIND ADDITIONAL INFORMATION; INCORPORATION BY REFERENCE</A></TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2pt"><A HREF="#sp04_007">24</A></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="m_001"></A>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As used in this prospectus, unless
the context otherwise requires, the terms &ldquo;Annovis,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; and &ldquo;our&rdquo;
refer to Annovis Bio,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This prospectus is a part of a
registration statement that we filed with the Securities and Exchange Commission, (the &ldquo;SEC&rdquo;), using a &ldquo;shelf&rdquo;
registration process. Under this shelf registration process, we may offer to sell any of the securities, or any combination of the securities,
described in this prospectus, in each case, in one or more offerings, up to an aggregate dollar amount of $250,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This prospectus provides you with a general
description of the securities that we may offer. Each time securities are sold under this registration statement, we will provide an
accompanying prospectus supplement that will contain specific information about the terms of those securities and the terms of that
offering. The accompanying prospectus supplement may also add, update or change information contained in this prospectus. If there
is any inconsistency between the information in this prospectus and any accompanying prospectus supplement, you should rely on the
information in the accompanying prospectus supplement. You should read both this prospectus and any accompanying prospectus
supplement, including all documents incorporated by reference herein and therein, together with the additional information described
under &ldquo;Where You Can Find Additional Information&rdquo; below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The information contained in this prospectus
is not complete and may be changed. You should rely only on the information provided in or incorporated by reference in this
prospectus or in any accompanying prospectus supplement, or documents to which we otherwise refer you. We have not authorized anyone
else to provide you with different information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>We have not authorized any
dealer, agent or other person to give any information or to make any representation other than those contained or incorporated by reference
in this prospectus and any accompanying prospectus supplement. You must not rely upon any information or representation not contained
or incorporated by reference in this prospectus or an accompanying prospectus supplement. This prospectus and the accompanying prospectus
supplement, if any, do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered
securities to which they relate, nor do this prospectus and any accompanying prospectus supplement, if any, constitute an offer to sell
or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation
in such jurisdiction. You should not assume that the information contained in this prospectus and any accompanying prospectus supplement
is accurate on any date subsequent to the date set forth on the front of such document or that any information we have incorporated by
reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus and any
accompanying prospectus supplement is delivered, or securities are sold on a later date.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="m_002"></A>FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This prospectus, including documents
incorporated by reference, any applicable prospectus supplement and any related free writing prospectus, contain forward-looking
statements, as defined in Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities
Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the words &ldquo;anticipate,&rdquo;
 &ldquo;believe,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo;
 &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;objective,&rdquo; &ldquo;ongoing,&rdquo; &ldquo;plan,&rdquo;
 &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;potential,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo; or
 &ldquo;would,&rdquo; and or the negative of these terms, or other comparable terminology intended to identify statements about the
future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels
of activity, performance or achievements to be materially different from the information expressed or implied by these
forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this
prospectus, we caution you that these statements are based on a combination of facts and factors currently known by us and our
expectations of the future, about which we cannot be certain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">The forward-looking statements
in this prospectus include, among other things, statements about:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>our business strategies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the timing of regulatory submissions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>our ability to obtain and maintain regulatory approval of our existing product candidates and any other product candidates we may
develop, and the labeling under any approval we may obtain;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>risks relating to the timing and costs of clinical trials and the timing and costs of other expenses;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>risks related to market acceptance of products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>risks associated with our reliance on third-party organizations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>our competitive position;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>assumptions regarding the size of the available market, product pricing and timing of commercialization of our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>our intellectual property position and our ability to maintain and protect our intellectual property rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>our results of operations, financial condition, liquidity, prospects, and growth strategies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>our cash needs and financing plans;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the industry in which we operate; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the trends that may affect the industry or us.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We cannot guarantee that the results and
other expectations expressed, anticipated or implied in any forward-looking statement will be realized. The risks set forth under
Item 1A of our Form&nbsp;10-K for the year ended December&nbsp;31, 2022, as revised or supplemented by our Quarterly Reports on
Form&nbsp;10-Q and other documents we file with the SEC, describe material risks to our business, and you should read and interpret
any forward-looking statements together with these risks. A variety of factors, including these risks, could cause our actual
results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or
implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove
inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the
forward-looking statements. You should bear this in mind as you consider any forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">You should read this prospectus,
including documents incorporated by reference, any applicable prospectus supplement and any related free writing prospectus completely
and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements
contained in this prospectus are made as of the date of this prospectus and we do not assume any obligation to update any forward-looking
statements, whether as a result of new information, future events or otherwise, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="m_003"></A>THE COMPANY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical stage, drug platform company addressing neurodegeneration, such as Alzheimer&rsquo;s disease (&ldquo;AD&rdquo;) and Parkinson&rsquo;s
disease (&ldquo;PD&rdquo;). We are developing our lead product candidate, buntanetap, which is designed to address AD, PD and other chronic
neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. In several
studies, buntanetap was observed to inhibit the synthesis of neurotoxic proteins-APP/A</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&beta;
</FONT>(&ldquo;APP&rdquo;), tau/phospho-tau (&ldquo;tau&rdquo;) and <FONT STYLE="font-family: Times New Roman, Times, Serif">&alpha;</FONT>-Synuclein
(&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">&alpha;</FONT>SYN&rdquo;)-that are the main causes of neurodegeneration.
High levels of neurotoxic proteins lead to impaired axonal transport, which is responsible for the communication between and within nerve
cells. When that communication is impaired, the immune system is activated and attacks the nerve cells, eventually killing them. We have
observed in our clinical studies in early AD and early PD patients and pre-clinical studies in mice and rats that buntanetap lowered neurotoxic
protein levels leading to improved axonal transport, reduced inflammation, lower nerve cell death and improved affected function.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In 2021, we completed two Phase 1/2 clinical
studies: one in 14 early AD patients, and one in 54 early PD patients (together, the &ldquo;AD/PD Trials&rdquo;). In the AD/PD Trials,
early AD patients were defined as those with a Mini Mental State Examination (MMSE) score between 19 and 28 and early PD patients as
those patients at Hoehn&nbsp;&amp; Yahr stages 1, 2 or 3. MMSE is a brief screening instrument used to assess cognitive function, with
total scores ranging from 0 to 30 and a lower score indicating greater disease severity, while the Hoehn&nbsp;&amp; Yahr scale is a medical
assessment used to measure staging of the functional disability associated with PD where a higher stage indicates greater disease severity.
In collaboration with the Alzheimer&rsquo;s Disease Cooperative Study (&ldquo;ADCS&rdquo;), we also conducted a trial in 16 early AD
patients (the &ldquo;ADCS Trial&rdquo;). In the ADCS Trial, early AD patients were defined as those patients with a MMSE score between
19 and 28. All three clinical trials were double-blind, placebo-controlled studies. We designed the studies by applying our understanding
of the underlying neurodegenerative disease states, and measured efficacy as well as both target and pathway engagement in the spinal
fluid of patients to determine whether patients improvement following treatment correlated with the CSF biomarkers. In addition to meeting
their primary endpoints of safety and tolerability and secondary endpoint of pharmacokinetics, our AD/PD Trials met exploratory endpoints
of measures of biomarkers and improvements in cognition in AD patients, and in function in PD patients. We believe that the AD/PD Trials
represent the first double-blind placebo-controlled studies that showed improvements in AD patients, as measured by ADAS-Cog, and in
PD patients, as measured by UPDRS. Following completion of the AD/PD Trials, we submitted our data to the U.S. Food and Drug Administration
(&ldquo;FDA&rdquo;) and requested direction to further pursue the development of buntanetap in early PD patients. With the FDA&rsquo;s
guidance, we initiated a Phase 3 study in early PD patients in August&nbsp;2022 (our &ldquo;Phase 3 PD Study&rdquo;). In the Phase 3
PD Study, early PD patients were defined as those at Hoehn&nbsp;&amp; Yahr stages 1, 2 or 3, and OFF times of less than two hours per
day. OFF time refers to when PD motor and/or non-motor symptoms occur between medication doses. We also submitted a proposed protocol
for the treatment of moderate AD to the FDA, and after receiving permission to proceed, we initiated a Phase 2/3 study in mild to moderate
AD patients in February&nbsp;2023 (our &ldquo;Phase 2/3 AD Study&rdquo;). In the Phase 2/3 AD Study, mild to moderate AD patients were
defined as those with a MMSE score between 14 and 24. At the completion of the ADCS Trial, the data showed that buntanetap is a translational
inhibitor in humans just like in animals, and we further observed that there was statistical improvement in cognition in early AD patients,
just like in the AD/PD Trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our Phase 3 PD Study and Phase 2/3 AD Study
each have built in interim analyses. Our Phase 3 PD Study incorporated an interim analysis at two months, the results of which were
disclosed on March&nbsp;31, 2023. The pre-planned interim analysis was conducted by our data analytics provider based on 132
patients from all cohorts collectively for which baseline and two-month data was available. As the interim analysis was conducted at
two months of the six-month endpoint and only on 132 patients, it may not be indicative of the results at six months for the full
patient population because as the trial progresses, clinical outcomes may materially change as patient enrollment continues. Based
on the results of the interim analysis, we proceeded with the Phase 3 PD Study as planned in accordance with the previously
established protocol. The data safety monitoring board (DSMB) also conducted an interim safety analysis and reported that buntanetap
was generally well-tolerated and the study should proceed as planned. We remain blinded to the Phase 3 PD Study and we do not have
safety or efficacy data from the trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The pre-planned interim analysis
for AD was based on 107 patients having completed six weeks of treatment. Based on the results of the interim analysis, which we disclosed
on October&nbsp;12, 2023, we are proceeding with the Phase 2/3 AD study as planned without the need to add additional patients. The data
safety monitoring board (DSMB) also conducted an interim safety analysis and reported that buntanetap was generally well-tolerated and
the study should proceed as planned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We plan to consult with the FDA following
completion of both studies, to obtain feedback on our additional AD and PD studies, including conducting an open label extension
study following the completion of the initial trials. Using the data from the Phase 3 PD Study, we intend to design an 18-month long
disease- modifying Phase 3 study in the same early PD patients. In addition, we intend to conduct a short 6-month study in advanced
PD patients during the second half of the 18-month disease modifying Phase 3 study, at which time we will define the advanced PD
patient population for the purposes of such study. Similarly, using the data from the Phase 2/3 AD Study interim analysis, we intend
to design an 18-month disease modifying Phase 3 study in the same early AD patient population. In addition, we intend to conduct a
short 6-month study in advanced AD patients during the second half of the 18-month disease modifying Phase 3 study, at which time we
will define the advanced AD patient population for the purposes of such study. We intend to announce the final data analyses from
our Phase 3 PD Study and Phase 2/3 AD Study during the first half of 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">By the end of 2026, our goal is
to have conducted the required pivotal studies for buntanetap to be able to file two new drug applications (&ldquo;NDAs&rdquo;) with the
FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that we are the only company developing a drug for AD and PD that is designed to inhibit more than one neurotoxic protein,
and has a mechanism of action designed to restore nerve cell axonal and synaptic activity. By improving brain function, our goal is
to treat memory loss and dementia associated with AD as well as body and brain function associated with PD. Based on pre-clinical
and clinical data collected to date, we believe that buntanetap has the potential to be the first drug to interfere with the
underlying mechanism of neurodegeneration, potentially enabling buntanetap to be the only drug to improve cognition in AD and motor
function in PD. The industry has encountered challenges in specifically targeting one neurotoxic protein, be it APP, tau or </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&alpha;</FONT>SYN,
indicating that doing so does not change the course of neurodegeneration. Our goal is to develop a disease modifying drug
(&ldquo;DMD&rdquo;) for patients with neurodegeneration by leveraging our clinical and pre-clinical data to inhibit the three most
relevant neurotoxic proteins. Studies have found that AD and PD are the most common neurodegenerative diseases in the U.S., and
accordingly these diseases present two unmet needs of the aging population and two potentially large U.S. markets if a DMD is
developed and approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have never been profitable
and have incurred net losses since inception. Our accumulated deficit at September&nbsp;30, 2023 was $88,045,693. We expect to incur losses
for the foreseeable future, and we expect these losses to increase as we continue our development of, and seek regulatory approvals for,
our product candidates. Because of the numerous risks and uncertainties associated with product development, we are unable to predict
the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated under the laws of the State of Delaware in 2008. Our principal executive offices are located at 101 Lindenwood Drive,
Suite&nbsp;225, Malvern, PA 19355 . Our telephone number is 484-875-3192. Our website address is </FONT>www.annovisbio.com. The information
contained in, or accessible through, our website does not constitute a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="m_004"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Investing in any securities offered pursuant
to this prospectus and the applicable prospectus supplement involves risk. The prospectus supplement applicable to each offering of
our securities will contain a discussion of the risks applicable to an investment in any such securities. Prior to making a decision
about investing in any securities offered, you should carefully consider the specific factors discussed under the heading
 &ldquo;Risk Factors&rdquo; in the applicable prospectus supplement, together with all of the other information contained or
incorporated by reference in the prospectus supplement or appearing or incorporated by reference in this prospectus. You should also
consider the risks, uncertainties and assumptions discussed under the heading &ldquo;Risk Factors&rdquo; in our most recent Annual
Report on Form&nbsp;10-K and any subsequent Quarterly Reports on Form&nbsp;10-Q and other documents that we file with the SEC, which
are incorporated herein by reference as described in this prospectus under the heading &ldquo;Where You Can Find Additional
Information&rdquo;. The risks and uncertainties we have described in such documents are not the only risks that we face. Additional
risks and uncertainties not presently known to us may also affect our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="m_005"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Except as otherwise provided in
the applicable prospectus supplement relating to a specific offering, we intend to use the net proceeds from the sale of securities by
us under this prospectus and any applicable prospectus supplement for general corporate purposes, which may include working capital, capital
expenditures, research and development expenditures, clinical trial expenditures, acquisitions of new technologies, products or businesses,
and investments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="m_006"></A>GENERAL DESCRIPTION OF OUR SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may offer and sell, at any time and from
time to time:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>shares of our common stock;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>shares of our preferred stock;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>various series of debt securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>warrants to purchase common shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>units consisting of a combination of the foregoing securities; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>any combination of these securities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This prospectus contains summary
descriptions of the common stock, preferred stock, debt securities, warrants, and units that we may offer and sell from time to time.
When particular securities are offered by us, a supplement to this prospectus will describe the terms of the securities and the extent
to which these general descriptions may apply. These summary descriptions and any summary descriptions in the applicable prospectus supplement
are not complete descriptions of the terms and conditions of each security and are qualified in their entirety by reference to our amended
and restated certificate of incorporation and our amended and restated bylaws which are incorporated by reference in the registration
statement of which this prospectus is a part. Please refer to &ldquo;Where You Can Find Additional Information&rdquo; below for directions
on obtaining these documents. If any particular terms of a security described in the applicable prospectus supplement differ from any
of the terms described in this prospectus, then the terms described in this prospectus will be deemed superseded by the terms set forth
in that prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="m_007"></A>DESCRIPTION OF OUR CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Authorized and Outstanding Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our authorized share capital consists of
72,000,000 shares of capital stock, each with a par value of $0.0001 per share. Of these shares, 70,000,000 shall be common stock
and 2,000,000 shall be preferred stock. As of January&nbsp;30, 2024, there were 10,579,933 shares of common stock outstanding and no
shares of preferred stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Voting</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The holders of our common stock
are entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. There is no cumulative
voting. An election of directors by our stockholders shall be determined by a plurality of the votes cast by stockholders entitled to
vote in the election. Subject to the supermajority votes for some matters, other matters shall be decided by the affirmative vote of our
stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Dividends</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Subject to the rights of holders
of all classes of our stock outstanding having rights that are senior to or equivalent to holders of common stock, the holders of the
common stock are entitled to receive proportionately any dividends when and as declared by our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Liquidation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the event of our liquidation,
dissolution or winding up, the holders of common stock are entitled to receive on a pro rata basis our net assets available for distribution
to stockholders after the payment of all debts and other liabilities, subject to the rights of holders of all classes of our stock outstanding
having rights that are senior to or equivalent to holders of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Other</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Holders of common stock have no preemptive,
subscription, redemption or conversion rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">All of our outstanding shares
of common stock are fully paid and nonassessable, and any shares of common stock to be issued upon an offering pursuant to this prospectus
and the related prospectus supplement will be fully paid and nonassessable upon issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the terms of our amended
and restated certificate of incorporation, our board of directors is authorized to direct us to issue shares of preferred stock in one
or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges
and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each
series of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We will fix the designations,
powers, preferences and rights of the preferred stock of each series, as well as the qualifications, limitations or restrictions thereon,
in the certificate of designation relating to that series. The applicable prospectus supplement will contain the terms of and other information
relating to the preferred stock which will include, as applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the title and stated value;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the number of shares we are offering;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the liquidation preference per share;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the purchase price; the dividend rate, period and payment date and method of calculation for dividends;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the procedures for any auction and remarketing, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the provisions for a sinking fund, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase
rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>any listing of the preferred stock on any securities exchange or market;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion price, or how it will be
calculated, and the conversion period;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>voting rights, if any, of the preferred stock;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>preemptive rights, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>restrictions on transfer, sale or other assignment, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>whether interests in the preferred stock will be represented by depositary shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>a discussion of any material United States federal income tax considerations applicable to the preferred stock;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up
our affairs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>any limitations on the issuance of any class or series of preferred stock ranking senior to or on a parity with the series of preferred
stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>any other specific terms, preferences, rights or limitations of, or restrictions on, the preferred stock.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our board of directors may authorize the
issuance of preferred stock with voting, conversion or other rights that could adversely affect the voting power or other rights of
the holders of our common stock. Preferred stock could be issued quickly with terms designed to delay or prevent a change in control
of our company or make removal of management more difficult. Additionally, the issuance of preferred stock may have the effect of
decreasing the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Anti-Takeover Effects of Delaware Law and Our Certificate
of Incorporation and Bylaws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Some provisions of Delaware law,
our amended and restated certificate of incorporation and our amended and restated bylaws could make the following transactions more difficult:
an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the removal of our
incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions
that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for
payment of a premium over the market price for our shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">These provisions, summarized below,
are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons
seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection
of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh
the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Authorized but Unissued Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our authorized but unissued shares of common
stock and preferred stock are available for future issuance without stockholder approval. These additional shares may be utilized
for a variety of corporate purposes, including future public offerings to raise additional capital and corporate acquisitions. The
existence of authorized but unissued shares of common stock and preferred stock could render more difficult or discourage an attempt
to obtain control of a majority of our common stock by means of a proxy contest, tender offer, merger or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Stockholder Meetings</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Any action to be taken by our
stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Requirements for Advance Notification of Stockholder
Nominations and Proposals</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Stockholders seeking to present
proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide
advance notice in writing, and also specify requirements as to the form and content of a stockholder&rsquo;s notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Delaware Anti-Takeover Statute</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are subject to Section&nbsp;203 of the
General Corporation Law of the State of Delaware, which prohibits persons deemed to be &ldquo;interested stockholders&rdquo; from
engaging in a &ldquo;business combination&rdquo; with a publicly held Delaware corporation for three years following the date these
persons become interested stockholders unless the business combination is, or the transaction in which the person became an
interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &ldquo;interested
stockholder&rdquo; is a person who, together with affiliates and associates, owns, or within three years prior to the determination
of interested stockholder status did own, 15% or more of a corporation&rsquo;s voting stock. Generally, a &ldquo;business
combination&rdquo; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested
stockholder. The existence of this provision may have an anti- takeover effect with respect to transactions not approved in advance
by the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Choice of Forum</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Court of Chancery of the State
of Delaware is the exclusive forum in which we and our directors may be sued by our stockholders, to the fullest extent permitted by law,
for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>any derivative action or proceeding brought on our behalf;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>any action asserting a breach of fiduciary duty;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate
of incorporation, or our amended and restated bylaws; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>or any action asserting a claim against us that is governed by the internal affairs doctrine.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our amended and restated bylaws
will not apply to suits brought to enforce a duty or liability created by the Securities Act or the Exchange Act, or any other claim for
which federal courts have exclusive jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">These choice of forum provisions
may limit a stockholder&rsquo;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our
directors, officers, or other employees, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to
find either choice of forum provision contained in our amended and restated bylaws to be inapplicable or unenforceable in an action, we
may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations,
and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Advance Notice Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our bylaws establish an advance notice procedure
for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election
to the board of directors. Stockholders at an annual meeting will only be able to consider proposals or nominations specified in the
notice of meeting or brought before the meeting by or at the direction of the board of directors or by a stockholder who was a stockholder
of record on the record date for the meeting, who is entitled to vote at the meeting and who has given our Secretary timely written notice,
in proper form, of the stockholder&rsquo;s intention to bring that business before the meeting. Although our bylaws do not give the board
of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted
at a special or annual meeting, our bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper
procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own
slate of directors or otherwise attempting to obtain control of us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Stock Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our common stock is listed on the NYSE under
the symbol &ldquo;ANVS.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The transfer agent and registrar for our common
stock is Equiniti Trust Company LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<!-- Field: Split-Segment; Name: 4 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B><A NAME="sp04_001"></A>DESCRIPTION
OF DEBT SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We may issue debt securities
from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While
the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe
the particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement. The terms of any
debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires otherwise,
whenever we refer to the indenture, we also are referring to any supplemental indentures that specify the terms of a particular series
of debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We will issue the debt securities
under the indenture that we will enter into with the trustee who will be named in the indenture. The indenture will be qualified under
the Trust Indenture Act of 1939, as amended (the &ldquo;Trust Indenture Act&rdquo;). We have filed the form of indenture as an exhibit
to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing
the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a
part or will be incorporated by reference from reports that we file with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">The following summary of material
provisions of the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions
of the indenture applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplement and any
related free writing prospectus related to the debt securities that we may offer under this prospectus, as well as the complete indenture
that contains the terms of the debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">The indenture will not limit
the amount of debt securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may
authorize and may be in any currency or currency unit that we may designate. Except for the limitations on consolidation, merger and
sale of all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or
other provisions designed to give holders of any debt securities protection against changes in our operations, financial condition or
transactions involving us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We may issue the debt securities
issued under the indenture as &ldquo;discount securities,&rdquo; which means they may be sold at a discount below their stated principal
amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued with &ldquo;original
issue discount,&rdquo; or OID, for U.S. federal income tax purposes because of interest payment and other characteristics or terms of
the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued with OID will be described
in more detail in any applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We will describe in the applicable
prospectus supplement the terms of the series of debt securities being offered, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the title of the series
                                            of debt securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any limit upon the
                                            aggregate principal amount that may be issued;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the maturity date
                                            or dates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the form of the debt
                                            securities of the series;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the applicability
                                            of any guarantees;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether or not the
                                            debt securities will be secured or unsecured, and the terms of any secured debt;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether the debt securities
                                            rank as senior debt, senior subordinated debt, subordinated debt or any combination thereof,
                                            and the terms of any subordination;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if the price (expressed
                                            as a percentage of the aggregate principal amount thereof) at which such debt securities
                                            will be issued is a price other than the principal amount thereof, the portion of the principal
                                            amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable,
                                            the portion of the principal amount of such debt securities that is convertible into another
                                            security or the method by which any such portion shall be determined;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the interest rate
                                            or rates, which may be fixed or variable, or the method for determining the rate and the
                                            date interest will begin to accrue, the dates interest will be payable and the regular record
                                            dates for interest payment dates or the method for determining such dates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our right, if any,
                                            to defer payment of interest and the maximum length of any such deferral period;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if applicable, the
                                            date or dates after which, or the period or periods during which, and the price or prices
                                            at which, we may, at our option, redeem the series of debt securities pursuant to any optional
                                            or provisional redemption provisions and the terms of those redemption provisions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the date or dates,
                                            if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory
                                            sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&rsquo;s
                                            option to purchase, the series of debt securities and the currency or currency unit in which
                                            the debt securities are payable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the denominations
                                            in which we will issue the series of debt securities, if other than denominations of $1,000
                                            and any integral multiple thereof;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any and all terms,
                                            if applicable, relating to any auction or remarketing of the debt securities of that series
                                            and any security for our obligations with respect to such debt securities and any other terms
                                            which may be advisable in connection with the marketing of debt securities of that series;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any and all terms,
                                            if applicable, relating to any auction or remarketing of the debt securities of that series
                                            and any security for our obligations with respect to such debt securities and any other terms
                                            which may be advisable in connection with the marketing of debt securities of that series;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any and all terms,
                                            if applicable, relating to any auction or remarketing of the debt securities of that series
                                            and any security for our obligations with respect to such debt securities and any other terms
                                            which may be advisable in connection with the marketing of debt securities of that series;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether the debt securities
                                            of the series shall be issued in whole or in part in the form of a global security or securities;
                                            the terms and conditions, if any, upon which such global security or securities may be exchanged
                                            in whole or in part for other individual securities; and the depositary for such global security
                                            or securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if applicable, the
                                            provisions relating to conversion or exchange of any debt securities of the series and the
                                            terms and conditions upon which such debt securities will be so convertible or exchangeable,
                                            including the conversion or exchange price, as applicable, or how it will be calculated and
                                            may be adjusted, any mandatory or optional (at our option or the holders&rsquo; option) conversion
                                            or exchange features, the applicable conversion or exchange period and the manner of settlement
                                            for any conversion or exchange;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if other than the
                                            full principal amount thereof, the portion of the principal amount of debt securities of
                                            the series which shall be payable upon declaration of acceleration of the maturity thereof;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>additions to or changes
                                            in the covenants applicable to the particular debt securities being issued, including, among
                                            others, the consolidation, merger or sale covenant;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>additions to or changes
                                            in the events of default with respect to the securities and any change in the right of the
                                            trustee or the holders to declare the principal, premium, if any, and interest, if any, with
                                            respect to such securities to be due and payable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>additions to or changes
                                            in or deletions of the provisions relating to covenant defeasance and legal defeasance;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>additions to or changes
                                            in the provisions relating to satisfaction and discharge of the indenture;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>additions to or changes
                                            in the provisions relating to the modification of the indenture both with and without the
                                            consent of holders of debt securities issued under the indenture;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the currency of payment
                                            of debt securities if other than U.S. dollars and the manner of determining the equivalent
                                            amount in U.S. dollars;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether interest will
                                            be payable in cash or additional debt securities at our or the holders&rsquo; option and
                                            the terms and conditions upon which the election may be made;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the terms and conditions,
                                            if any, upon which we will pay amounts in addition to the stated interest, premium, if any
                                            and principal amounts of the debt securities of the series to any holder that is not a &ldquo;United
                                            States person&rdquo; for federal tax purposes;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any restrictions on
                                            transfer, sale or assignment of the debt securities of the series; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any other specific
                                            terms, preferences, rights or limitations of, or restrictions on, the debt securities, any
                                            other additions or changes in the provisions of the indenture, and any terms that may be
                                            required by us or advisable under applicable laws or regulations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>Conversion or Exchange Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We will set forth in the applicable
prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable for our common stock or
our other securities. We will include provisions as to settlement upon conversion or exchange and whether conversion or exchange is mandatory,
at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock or
our other securities that the holders of the series of debt securities receive would be subject to adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>Consolidation, Merger or Sale</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">Unless we provide otherwise in
the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain any covenant that restricts
our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as
an entirety. However, any successor to or acquirer of such assets (other than a subsidiary of ours) must assume all of our obligations
under the indenture or the debt securities, as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>Events of Default under the Indenture</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">Unless we provide otherwise in
the prospectus supplement applicable to a particular series of debt securities, the following are events of default under the indenture
with respect to any series of debt securities that we may issue:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if we fail to pay
                                            any installment of interest on any series of debt securities, as and when the same shall
                                            become due and payable, and such default continues for a period of 90 days; provided, however,
                                            that a valid extension of an interest payment period by us in accordance with the terms of
                                            any indenture supplemental thereto shall not constitute a default in the payment of interest
                                            for this purpose;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if we fail to pay
                                            the principal of, or premium, if any, on any series of debt securities as and when the same
                                            shall become due and payable whether at maturity, upon redemption, by declaration or otherwise,
                                            or in any payment required by any sinking or analogous fund established with respect to such
                                            series; provided, however, that a valid extension of the maturity of such debt securities
                                            in accordance with the terms of any indenture supplemental thereto shall not constitute a
                                            default in the payment of principal or premium, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if we fail to observe
                                            or perform any other covenant or agreement contained in the debt securities or the indenture,
                                            other than a covenant specifically relating to another series of debt securities, and our
                                            failure continues for 90 days after we receive written notice of such failure, requiring
                                            the same to be remedied and stating that such is a notice of default thereunder, from the
                                            trustee or holders of at least 25% in aggregate principal amount of the outstanding debt
                                            securities of the applicable series; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if specified events
                                            of bankruptcy, insolvency or reorganization occur.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">If an event of default with respect
to debt securities of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the
trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to
us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal of, premium, if any, and accrued
interest, if any, due and payable immediately. If an event of default specified in the last bullet point above occurs with respect to
us, the principal amount of and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable
without any notice or other action on the part of the trustee or any holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">The holders of a majority in
principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect to the
series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless
we have cured the default or event of default in accordance with the indenture. Any waiver shall cure the default or event of default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">Subject to the terms of the indenture,
if an event of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its
rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities,
unless such holders have offered the trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding debt
securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available
to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the direction so given
                                            by the holder is not in conflict with any law or the applicable indenture; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>subject to its duties
                                            under the Trust Indenture Act, the trustee need not take any action that might involve it
                                            in personal liability or might be unduly prejudicial to the holders not involved in the proceeding.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">A holder of the debt securities
of any series will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other
remedies only if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the holder has given
                                            written notice to the trustee of a continuing event of default with respect to that series;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the holders of at
                                            least 25% in aggregate principal amount of the outstanding debt securities of that series
                                            have made written request,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>such holders have
                                            offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities
                                            to be incurred by the trustee in compliance with the request; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the trustee does not
                                            institute the proceeding, and does not receive from the holders of a majority in aggregate
                                            principal amount of the outstanding debt securities of that series other conflicting directions
                                            within 90 days after the notice, request and offer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">These limitations do not apply
to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the
debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We will periodically file statements
with the trustee regarding our compliance with specified covenants in the indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>Modification of Indenture; Waiver</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We and the trustee may change
an indenture without the consent of any holders with respect to specific matters:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to cure any ambiguity,
                                            defect or inconsistency in the indenture or in the debt securities of any series;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to comply with the
                                            provisions described above under &ldquo;Description of Debt Securities &mdash; Consolidation,
                                            Merger or Sale;&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to provide for uncertificated
                                            debt securities in addition to or in place of certificated debt securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to add to our covenants,
                                            restrictions, conditions or provisions such new covenants, restrictions, conditions or provisions
                                            for the benefit of the holders of all or any series of debt securities, to make the occurrence,
                                            or the occurrence and the continuance, of a default in any such additional covenants, restrictions,
                                            conditions or provisions an event of default or to surrender any right or power conferred
                                            upon us in the indenture;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to add to, delete
                                            from or revise the conditions, limitations, and restrictions on the authorized amount, terms,
                                            or purposes of issue, authentication and delivery of debt securities, as set forth in the
                                            indenture;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to make any change
                                            that does not adversely affect the interests of any holder of debt securities of any series
                                            in any material respect;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to provide for the
                                            issuance of and establish the form and terms and conditions of the debt securities of any
                                            series as provided above under &ldquo;Description of Debt Securities &mdash; General&rdquo;
                                            to establish the form of any certifications required to be furnished pursuant to the terms
                                            of the indenture or any series of debt securities, or to add to the rights of the holders
                                            of any series of debt securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to evidence and provide
                                            for the acceptance of appointment under any indenture by a successor trustee; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to comply with any
                                            requirements of the SEC in connection with the qualification of any indenture under the Trust
                                            Indenture Act.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">In addition, under the indenture,
the rights of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of
at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless
we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may make the
following changes only with the consent of each holder of any outstanding debt securities affected:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>extending the fixed
                                            maturity of any debt securities of any series;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">reducing the principal
                                            amount, reducing the rate of or extending the time of payment of interest, or reducing any
                                            premium payable upon the redemption of any series of any debt securities; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>reducing the percentage
                                            of debt securities, the holders of which are required to consent to any amendment, supplement,
                                            modification or waiver.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>Discharge</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">The indenture provides that we
can elect to be discharged from our obligations with respect to one or more series of debt securities, except for specified obligations,
including obligations to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>provide for payment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>register the transfer
                                            or exchange of debt securities of the series;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>replace stolen, lost
                                            or mutilated debt securities of the series;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>pay principal of and
                                            premium and interest on any debt securities of the series;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>maintain paying agencies</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>hold monies for payment
                                            in trust;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>recover excess money
                                            held by the trustee;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>compensate and indemnify
                                            the trustee; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>appoint any successor
                                            trustee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">In order to exercise our rights
to be discharged, we must deposit with the trustee money or government obligations sufficient to pay all the principal of, any premium,
if any, and interest on, the debt securities of the series on the dates payments are due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>Form, Exchange and Transfer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We will issue the debt securities
of each series only in fully registered form without coupons and, unless we provide otherwise in the applicable prospectus supplement,
in denominations of $1,000 and any integral multiple thereof. The indenture provides that we may issue debt securities of a series in
temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company,
or DTC, or another depositary named by us and identified in the applicable prospectus supplement with respect to that series. To the
extent the debt securities of a series are issued in global form and as book-entry, a description of terms relating such securities will
be set forth in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">At the option of the holder,
subject to the terms of the indenture and the limitations applicable to global securities described in the applicable prospectus supplement,
the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any
authorized denomination and of like tenor and aggregate principal amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">Subject to the terms of the indenture
and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt securities
may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon
duly executed if so required by us or the security registrar, at the office of the security registrar or at the office of any transfer
agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange,
we will impose no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental
charges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We will name in the applicable
prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate
for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or
approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in
each place of payment for the debt securities of each series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">If we elect to redeem the debt
securities of any series, we will not be required to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>issue, register the
                                            transfer of, or exchange any debt securities of that series during a period beginning at
                                            the opening of business 15 days before the day of mailing of a notice of redemption of any
                                            debt securities that may be selected for redemption and ending at the close of business on
                                            the day of the mailing; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>register the transfer
                                            of or exchange any debt securities so selected for redemption, in whole or in part, except
                                            the unredeemed portion of any debt securities we are redeeming in part.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>Information Concerning the Trustee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">The trustee, other than during
the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically
set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a
prudent person would exercise or use in the conduct of his or her own affairs. Subject to this provision, the trustee is under no obligation
to exercise any of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable
security and indemnity against the costs, expenses and liabilities that it might incur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>Payment and Paying Agents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">Unless we otherwise indicate
in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to
the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular
record date for the interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We will pay principal of and
any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us, except that
unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the
holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate
the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will
name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular
series. We will maintain a paying agent in each place of payment for the debt securities of a particular series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"></P>

<!-- Field: Page; Sequence: 6; Value: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">All money we pay to a paying
agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at
the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the
debt security thereafter may look only to us for payment thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>Governing Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">The indenture and the debt securities
will be governed by and construed in accordance with the internal laws of the State of New York, except to the extent that the Trust
Indenture Act is applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B><A NAME="sp04_002"></A>DESCRIPTION
OF OUR WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We may issue warrants to purchase
our common stock, preferred stock and/or debt securities in one or more series. We may issue warrants independently or together with
common stock, preferred stock or debt securities, and the warrants may be attached to or separate from these securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">The terms of each series of warrants
will be contained in the applicable warrant agreements. The applicable prospectus supplement for the warrants will contain the terms
of and other information relating to the warrants which will include, as applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the offering price
                                            and aggregate number of warrants offered;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the currency in which
                                            the offering price, if any, and the exercise price are payable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the designation and
                                            terms of the securities with which the warrants are issued and the number of warrants issued
                                            with each such security or each principal amount of such security;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the date on and after
                                            which the warrants and the related securities will be separately transferable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>in the case of warrants
                                            to purchase common stock or preferred stock, the exercise price and the number of shares
                                            of common stock or preferred stock, as applicable, to be received upon exercise of the warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>in the case of warrants
                                            to purchase debt securities, the principal amount of debt securities purchasable upon exercise
                                            of one warrant and the price at, and currency in which, this principal amount of debt securities
                                            may be purchased upon such exercise;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the date on which
                                            the right to exercise the warrants will begin and the date on which that right will expire
                                            or, if the warrants may not be continuously exercised throughout that period, the specific
                                            date or dates on which the warrants may be exercised;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a discussion of any
                                            material United States federal income tax considerations related to the holding or exercise
                                            of the warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the identity of the
                                            warrant agent for the warrants, if any, and of any other depositaries, execution or paying
                                            agents, transfer agents, registrars or other agents;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any provisions for
                                            changes to or adjustments in the exercise price or number of securities issuable upon exercise
                                            of the warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the designation and
                                            terms of the securities issuable upon exercise of the warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the minimum or maximum
                                            amount of the warrants that may be exercised at any one time;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the anti-dilution
                                            provisions of the warrants, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the rights to redeem
                                            or call the warrants, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the effect of any
                                            merger, consolidation, sale or other disposition of our business on the warrant agreement
                                            and the warrants; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any other specific
                                            terms, preferences, rights and limitations of or restrictions on the warrants.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">Before the exercise of their
warrants, holders of warrants will not have any of the rights of holders of the securities issuable upon exercise. Holders of warrants
to purchase common stock or preferred stock will not be entitled to vote, consent, receive dividends, receive notice as stockholders
with respect to any meeting of stockholders for the election of our directors, receive payments upon our liquidation, dissolution or
winding up, or to exercise any rights whatsoever as our stockholders. In the case of warrants to purchase debt securities, holders of
warrants will not have the right to receive payments of principal of, or premium, if any, or interest on, the debt securities purchasable
upon exercise or to enforce covenants in the applicable indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">The transfer agent and registrar
for any warrants will be set forth in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"></P>

<!-- Field: Page; Sequence: 8; Value: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B><A NAME="sp04_003"></A>DESCRIPTION
OF OUR UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">The following description, together
with the additional information we include in any applicable prospectus supplement, summarizes the material terms and provisions of the
units that we may offer under this prospectus. Units may be offered independently or together with common stock, preferred stock or warrants
offered by any prospectus supplement, and may be attached to or separate from those securities. While the terms we have summarized below
will generally apply to any future units that we may offer under this prospectus, we will describe the particular terms of any series
of units that we may offer in more detail in the applicable prospectus supplement. The terms of any units offered under an applicable
prospectus supplement may differ from the terms described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We will incorporate by reference
into the registration statement of which this prospectus forms a part the form of unit agreement, including a form of unit certificate,
if any, that describes the terms of the series of units we are offering before the issuance of the related series of units. The following
summaries of material provisions of the units, and the unit agreements, are subject to, and qualified in their entirety by reference
to, all the provisions of the unit agreement applicable to a particular series of units. We urge you to read the applicable prospectus
supplements related to the units that we sell under this prospectus, as well as the complete unit agreements that contain the terms of
the units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We may issue units comprised
of one or more of the securities described in this prospectus in any combination. Each unit will be issued so that the holder of the
unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder
of each included security. The unit agreement, if any, under which a unit is issued may provide that the securities comprising the unit
may not be held or transferred separately, at any time or at any time before a specified date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">The particular terms and provisions
of units offered by an applicable prospectus supplement, and the extent to which the general terms and provisions described below may
apply thereto, will be described in the applicable prospectus supplement filed in respect of such units. This description will include,
where applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the designation and
                                            aggregate number of units offered;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the price at which
                                            the units will be offered;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the rights and obligations
                                            of the unit agent, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the currency or currencies
                                            in which the units are denominated;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any provisions of
                                            the governing unit agreement that differ from those described below;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the terms of the units
                                            and of the securities comprising the units, including whether and under what circumstances
                                            those securities may be held or transferred separately;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the number of securities
                                            that may be purchased upon exercise of each unit and the price at which the currency or currencies
                                            in which that amount of securities may be purchased upon exercise of each unit;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any provisions for
                                            the issuance, payment, settlement, transfer, adjustment or exchange of the units or of the
                                            securities comprising the units; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any other material
                                            terms of the units.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We reserve the right to set forth
in an applicable prospectus supplement specific terms of the units that are not within the options and parameters set forth in this prospectus.
In addition, to the extent that any particular terms of the units described in an applicable prospectus supplement differ from any of
the terms described in this prospectus, the description of such terms set forth in this prospectus shall be deemed to have been superseded
by the description of the differing terms set forth in such prospectus supplement with respect to such units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"></P>

<!-- Field: Page; Sequence: 9; Value: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B><A NAME="sp04_004"></A>PLAN
OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We may sell the securities, from
time to time, to or through underwriters or dealers, through agents or remarketing firms, or directly to one or more purchasers pursuant
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>underwritten public
                                            offerings;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>negotiated transactions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>block trades;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">&ldquo;At the Market
                                            Offerings,&rdquo; within the meaning of Rule&nbsp;415(a)(4)&nbsp;of the Securities Act of
                                            1933, as amended, or the Securities Act, into an existing trading market, at prevailing market
                                            prices; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>through a combination
                                            of these methods.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We may sell the securities to
or through one or more underwriters or dealers (acting as principal or agent), through agents, or directly to one or more purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We may distribute securities
from time to time in one or more transactions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at a fixed price or
                                            prices, which may be changed;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at market prices prevailing
                                            at the time of sale;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at prices related
                                            to such prevailing market prices; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at negotiated prices.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">A prospectus supplement or supplements
(and any related free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of the
securities, including, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the name or names
                                            of the underwriters, dealers or agents, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if the securities
                                            are to be offered through the selling efforts of brokers or dealers, the plan of distribution
                                            and the terms of any agreement, arrangement, or understanding entered into with broker(s)&nbsp;or
                                            dealer(s)&nbsp;prior to the effective date of the registration statement, and, if known,
                                            the identity of any broker(s)&nbsp;or dealer(s)&nbsp;who will participate in the offering
                                            and the amount to be offered through each;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the purchase price
                                            of the securities or other consideration therefor, and the proceeds, if any, we will receive
                                            from the sale;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if any of the securities
                                            being registered are to be offered otherwise than for cash, the general purposes of the distribution,
                                            the basis upon which the securities are to be offered, the amount of compensation and other
                                            expenses of distribution, and by whom they are to be borne;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any delayed delivery
                                            arrangements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any over-allotment
                                            or other options under which underwriters may purchase additional securities from us;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any agency fees or
                                            underwriting discounts and other items constituting agents&rsquo; or underwriters&rsquo;
                                            compensation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any public offering
                                            price;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any discounts, commissions
                                            or concessions allowed or reallowed or paid to dealers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the identity and relationships
                                            of any finders, if applicable; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any securities exchange
                                            or market on which the securities may be listed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">In compliance with the guidelines
of FINRA, the maximum compensation to the underwriters or dealers in connection with the sale by the Company of its securities pursuant
to this prospectus and the accompanying supplement to this prospectus may not exceed 8% of the aggregate offering price of the securities
as set forth on the cover page&nbsp;of any prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"></P>

<!-- Field: Page; Sequence: 10; Value: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">Only underwriters named in the
prospectus supplement will be underwriters of the securities offered by the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">If underwriters are used in the
sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more transactions
at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase
the securities will be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities to the
public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Unless otherwise
indicated in the prospectus supplement, subject to certain conditions, the underwriters will be obligated to purchase all of the securities
offered by the prospectus supplement, other than securities covered by any underwriter&rsquo;s option. Any public offering price and
any discounts or concessions allowed or reallowed or paid to dealers may change from time to time. We may use underwriters, dealers or
agents with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, dealer or agent,
the nature of any such relationship.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We may use a remarketing firm
to offer the securities in connection with a remarketing arrangement upon their purchase. Remarketing firms will act as principals for
their own account or as agents for us. These remarketing firms will offer or sell the securities pursuant to the terms of the securities.
A prospectus supplement will identify any remarketing firm and the terms of its agreement, if any, with us and will describe the remarketing
firm&rsquo;s compensation. Remarketing firms may be deemed to be underwriters in connection the securities they remarket.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">If we offer and sell securities
through a dealer, we or an underwriter will sell the securities to the dealer, as principal. The dealer may then resell the securities
to the public at varying prices to be determined by the dealer at the time of resale. The name of the dealer and the terms of the transaction
will be set forth in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We may sell securities directly
or through agents we designate from time to time. We will name any agent involved in the offering and sale of securities and we will
describe any commissions payable to the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, the agent
will act on a best-efforts basis for the period of its appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">Dealers and agents participating
in the distribution of the securities may be deemed to be underwriters, and compensation received by them on resale of the securities
may be deemed to be underwriting discounts. If such dealers or agents were deemed to be underwriters, they may be subject to statutory
liabilities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We may sell securities directly
to one or more purchasers without using underwriters or agents. Underwriters, dealers and agents that participate in the distribution
of the securities may be underwriters as defined in the Securities Act, and any discounts or commissions they receive from us and any
profit on their resale of the securities may be treated as underwriting discounts and commissions under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We may authorize agents or underwriters
to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price set forth in
the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future.
We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus
supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We may provide agents, underwriters
and dealers with indemnification against civil liabilities, including liabilities under the Securities Act, or contribution with respect
to payments that the agents, underwriters or dealers may make with respect to these liabilities. Agents, underwriters and dealers, or
their respective affiliates, may engage in transactions with, or perform services for, us in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">The securities we offer may be
new issues of securities and may have no established trading market. The securities may or may not be listed on a securities exchange.
Underwriters may make a market in these securities but will not be obligated to do so and may discontinue any market making at any time
without notice. We can make no assurance as to the liquidity of, or the existence of trading markets for, any of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">Any underwriter may engage in
over-allotment, stabilizing transactions, short-covering transactions and penalty bids in accordance with Regulation M under the Securities
Exchange Act of 1934, as amended, or the Exchange Act. Over-allotment involves sales in excess of the offering size, which create a short
position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified
maximum price. Syndicate-covering or other short-covering transactions involve purchases of the securities, either through exercise of
the over-allotment option or in the open market after the distribution is completed, to cover short positions. Penalty bids permit the
underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing
or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise
be. If commenced, the underwriters may discontinue any of the activities at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">Any underwriters that are qualified
market makers on the NYSE may engage in passive market making transactions in the common stock on the NYSE in accordance with Regulation
M under the Exchange Act, during the business day prior to the pricing of the offering, before the commencement of offers or sales of
the common stock. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market
makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security;
if all independent bids are lowered below the passive market maker&rsquo;s bid, however, the passive market maker&rsquo;s bid must then
be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level
above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"></P>

<!-- Field: Page; Sequence: 12; Value: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B><A NAME="sp04_005"></A>LEGAL
MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">Unless otherwise specified in
a prospectus supplement, certain legal matters relating to the securities will be passed upon for us by Loeb&nbsp;&amp; Loeb LLP. As
appropriate, legal counsel representing the underwriters, dealers or agents will be named in the accompanying prospectus supplement and
may opine to certain legal matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B><A NAME="sp04_006"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">The financial statements of Annovis
Bio,&nbsp;Inc. as of December&nbsp;31, 2022 and 2021 and for the years then ended have been incorporated by reference herein in reliance
upon the report (which report includes an explanatory paragraph about the existence of substantial doubt concerning our ability to continue
as a going concern) of WithumSmith+Brown, PC, independent registered public accounting firm, incorporated by reference herein, upon the
authority of said firm as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B><A NAME="sp04_007"></A>WHERE
YOU CAN FIND ADDITIONAL INFORMATION; INCORPORATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>Available Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains an Internet website
at </FONT>http://www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file
electronically with the SEC. Our reports on Forms 10-K, 10-Q and 8-K, and amendments to those reports, are also available for download,
free of charge, as soon as reasonably practicable after these reports are filed with, or furnished to, the SEC, at our website at www.annovisbio.com.
Information contained on or accessible through our website is not a part of this prospectus or any prospectus supplement, and the inclusion
of our website address in this prospectus is an inactive textual reference only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B>Incorporation by Reference</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">The SEC allows us to &ldquo;incorporate
by reference&rdquo; into this prospectus the information in other documents that we file with it. This means that we can disclose important
information to you by referring you to those documents. The information incorporated by reference is considered to be a part of this
prospectus, and information in documents that we file later with the SEC will automatically update and supersede information contained
in documents filed earlier with the SEC or contained in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">We incorporate by reference in
this prospectus the documents listed below and any future filings that we may make with the SEC under Sections 13(a), 13(c), 14, or 15(d)&nbsp;of
the Exchange Act in this prospectus, between the date of this prospectus and the termination of the offering of the securities described
in this prospectus. We are not, however, incorporating by reference any documents, information or portions thereof deemed to have been
furnished and not filed, including any information that we disclose under Items 2.02 or 7.01 of any Current Report on Form&nbsp;8-K or
related exhibits furnished pursuant to Item 9.01 of Form&nbsp;8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">This prospectus and any accompanying
prospectus supplement incorporate by reference the documents set forth below that have previously been filed with the SEC:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923040275/anvs-20221231x10k.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Symbol">&middot;</FONT></A></TD><TD><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923040275/anvs-20221231x10k.htm" STYLE="-sec-extract: exhibit">our Annual Report
                                            on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2022 as filed with the SEC
                                            on March&nbsp;31, 2023;</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our Quarterly Reports
                                            on Form&nbsp;10-Q for the quarters ended March&nbsp;31, 2023, June&nbsp;30, 2023 and September&nbsp;30,
                                            2023, filed with the SEC on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000155837023009142/anvs-20230331x10q.htm" STYLE="-sec-extract: exhibit">May&nbsp;10, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000155837023014884/anvs-20230630x10q.htm" STYLE="-sec-extract: exhibit">August&nbsp;14, 2023</A> and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000155837023018298/anvs-20230930x10q.htm" STYLE="-sec-extract: exhibit">November&nbsp;8, 2023</A>, respectively;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our Current Reports
                                            on Form&nbsp;8-K as filed with the SEC on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923001850/tm232502d1_8k.htm" STYLE="-sec-extract: exhibit">January&nbsp;6, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923019581/tm236582d1_8k.htm" STYLE="-sec-extract: exhibit">February&nbsp;13, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923029078/tm238624d1_8k.htm" STYLE="-sec-extract: exhibit">March&nbsp;6, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923039748/tm2310923d1_8k.htm" STYLE="-sec-extract: exhibit">March&nbsp;31, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923041009/tm2311180d2_8k.htm" STYLE="-sec-extract: exhibit">April&nbsp;3, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923041237/tm2311180d3_8k.htm" STYLE="-sec-extract: exhibit">April&nbsp;4, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923066171/tm2317351d1_8k.htm" STYLE="-sec-extract: exhibit">May&nbsp;30, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923072250/tm2318997d1_8k.htm" STYLE="-sec-extract: exhibit">June&nbsp;16, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923108892/tm2328385d1_8k.htm" STYLE="-sec-extract: exhibit">October&nbsp;13, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923112633/tm2329368d2_8k.htm" STYLE="-sec-extract: exhibit">October&nbsp;30, 2023</A> and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923113281/tm2329368d4_8k.htm" STYLE="-sec-extract: exhibit">November&nbsp;1, 2023</A> (except information
                                            included pursuant to Items 2.02 or 7.01 and exhibits related to such items);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"></P>

<!-- Field: Page; Sequence: 13; Value: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the information specifically
                                            incorporated by reference into our <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1477845/000110465923040275/anvs-20221231x10k.htm" STYLE="-sec-extract: exhibit">Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2022</A> from our <A HREF="https://www.sec.gov/Archives/edgar/data/1477845/000110465923052107/tm2312833d3_def14a.htm" STYLE="-sec-extract: exhibit">Definitive Proxy Statement filed with the SEC on April&nbsp;28, 2023</A> (other
                                            than the portions thereof that are furnished and not filed); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #231f20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><A HREF="https://www.sec.gov/Archives/edgar/data/1477845/000110465921140386/tm2133159d1_8a12b.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Symbol">&middot;</FONT></A></TD><TD><A HREF="https://www.sec.gov/Archives/edgar/data/1477845/000110465921140386/tm2133159d1_8a12b.htm" STYLE="-sec-extract: exhibit">the description of
                                            our capital stock contained in our Registration Statement on Form&nbsp;8-A filed with the
                                            SEC on November&nbsp;17, 2021 and any amendments or supplements thereto.</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: #231f20">You may request, orally or in
writing, a copy of any or all of the documents incorporated herein by reference. These documents will be provided to you at no cost,
by contacting: Annovis Bio,&nbsp;Inc., <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101 Lindenwood Drive,
Suite&nbsp;225, Malvern, PA 19355. In addition, copies of any or all of the documents incorporated herein by reference may be accessed
at our website at </FONT>www.annovisbio.com. The information on such website is not incorporated by reference and is not a part of this
prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm248202d5_424b5img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><FONT STYLE="font-size: 10pt"><B>ANNOVIS
BIO,&nbsp;INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><FONT STYLE="font-size: 10pt"><B>316,455
Shares of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><FONT STYLE="font-size: 10pt"><B>PROSPECTUS
SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><FONT STYLE="font-size: 10pt"><B>MARCH&nbsp;21,
2024</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm248202d5_424b5img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm248202d5_424b5img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "" /H# 2(  A$! Q$!_\0
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MG/#>;X;%T)4)SPT,P2YGC<IQTZ*;E@LTRU9C1KRE"HZ4XT*M*$ZM*GR_D_\
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M$23;C)A0#[^,B D%T!!VD%AD-C=@\\':0<'G!STI_7I7\I_[.?\ P="_#?\
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MI.45)-2>\Y)?V-"Y4MMV.,EP@Q\[^6[(Y"?>"90E7("NI!4G-?S1_P#!T_\
MM=^%OV=?^"5?Q4^%%UK5M;?$O]K?5]&^"_PXT&%U>_U71+#Q#H?B/XI:V]FS
MI/\ V%H'@FSNM(U74HDDAM/$/B?PK9D.FIF2'YJ_;%_X/"_^"?'PG\.M#^R9
MX-^(W[8'CJ^MYVC%WHGB#X ?#/0KA)A#%_PD_B3XE^%3XUN+RW79/!I'A[X?
MZE9:HL,MO<:YHT\R,G\DWPZ\'_\ !0O_ (.9_P#@HKI6M>/]0U==#FF6W\6>
M.M(\-ZN/@E^RS\#]/N!/=:3X5L;[5+*P6Y^U2R?V9H,>H#Q/XV\=:A/K%_J%
MP);VZMW=I-=&K,(MQG3J*W-2G[2%TFE+V=6E=Q>DER5IV3T3Y9;Q1_2[_P &
M6'[/6I^%?V9OVLOVE=6TQK:W^,OQ4\(?#KPEJ4R R:EX?^%&EZC-J-S:@*66
MQ'BCQOJ>G-(K?-<Z5<^<BB)&/]M=Q&3$!E0%=2Q)(.#(I.QMRE9,$B-PP9)-
MKH=ZK7S-^R!^R7\&OV(_V?/AG^S9\ M!F\/_  P^&6EC3=$M+V5+S5]1OKN2
MXNM<\3Z_J:I$VH^(_$>IW=SJ6L7ACCMY)IFCMK6! C+]/3J'A=&&58!64@,&
M4D HRD89'&5=>"5)"LI(81&*C>W7?7^O^"#;?+=M\M.G2C=MVA24HPBK[)*4
MMK7;;M=N_P#EU?\ !6'PMJ__  1[_P"#C3PQ^U3X-M'\,_"OXA_%KP-^UKH+
MZ:+][*;PY\1]7ET/]I70Y( JP-<MX\M_B9JS>&(I9+33-'UWPY"(%MKF$5]D
M?\'B_P"VGIWQ=^)7[&/[#_PIU2ZUS2M*\,6G[3WCC3[&ZMI-.\1>+?BW8Q^"
MO@-IS>7,[P^(/#_@ZQ\8:O/"5CMIM%^*>B3VLTK27+P_L]_P=F_L%Z!^T9_P
M3RO?VE=$\.F_^,/[(FN6'C*RUG3[0'4KWX4^*+_3] ^)>@WDFZ6233[9/[&\
M30[()IDO-"MEE<12W=R?Y+/^#>K]DKQ'_P %4/\ @J1X.\?_ +2/B'Q1\3/
MW[*'@'PG\5/'&J:T?[3L==@^#,7@[X=_ #X8WVHS ?9].EEL](NK>T:-I=<\
M,^!_$UA%;VQM)]0DH1_HT?\ !)3]C^R_86_X)\?LP?LWIIL&F^)/!WPUTK5O
MB((H9(9;OXE>- WB[QS=7*2_O$N3XAUB]AGA8E8'A,*%E16/Z./]^+_>;_T6
MU5+)57?D*)L'S2%$;,QFF9G,:DKM:0N1*#F1MQVJ HJ:>1D>+:JG$D0.YS&,
M3/Y)VL4*,ZAMZQ[@\F-HP2I(!_DF?\$SO^5F_P"&_P#VD*_:+_\ 3]\7:_U>
M_B%\3/A[\)O#&H>-?BEXZ\*_#CP9I,]G%J/BSQIK^G>%_#MA-JM__9^G17VM
M:Q<6FFV[WE])':P++<*6FDC3!+@'_*"_X)CDW'_!S)\,KH(55_\ @H/^T*S)
MN1S&TVL_%Z54+(Q#$*C?,!M.TL#M*EO]&W_@LC^R9JW[<G_!-/\ :M_9Z\)V
MOVSQGXL\"?\ "3>!+ Q@'4/'7@'4]'\=>%M/D5Y(Y#>7^HZ#9V5HD67W21QE
M7+&$@'VSX-^(G[/G[27@O6KGP!XX^%/QX^'ESJ>I>%_$A\+>(O#7Q(\$W%^\
M5O+J^@:]::=J&KZ%?W7E7]E)<:=J$,FV/4[*X%MY5U$TG\Q'_!>S_@@+^PCX
MN_8F_::_:G_9R^ O@3]G7]H7X"_#;Q9\>TU#X46<O@;P-XU\+_#71;OQ1\2?
M#GB#X::++;_#R'4+_P %Z7K6JZ7KOAWPQHGB)_$UI8)>:G+9W%YYG\V/_!O'
M_P %P?"?_!)3Q5\7/V7_ -K7P7XNL/V>_B1X_M_%NK^(]!T6^N_'/P0^+FD:
M+8^"/$=[XB\ QG3+S7_#'B#2-!TG3?$=CIL%UXH\,:MX7L-3M-)\3.\L _7;
M_@MA_P '1G[)WQ8_9-^+O[(_[!;>)OBYXC_:)^'.O_#+Q[\:=>\'^(?AWX!\
M ?#3QII\N@?$'1O#^C>-M-L?%'BWQGXF\(3:[X7LISI6A>%]!76DUQ-?UB]T
MQ=%N@!G_  92?M*^+?$/A+]KG]D_7=;U+4/"7P]NO!?QA\ Z3>W4MUI_A5?%
MUQJ'AOQGI^AQSL_]G6NOZQ9:3K.HP6;)!<ZM;R78CA:XNA=_WE5_%E_P9T?L
M-^,?@M^S?\:_VR_'WAO4M%F_:9UW0/!GPNL]3M+K3+_4?A?\/9+R34O'"6M_
M#;Q2Z%XH\97DT&C3QNDK+H&I2*EQ!)8377]IM 'XA?\ !1+_ ((&_L8_\%.?
MC3HWQS_:2\2_'(^*?#OP]TSX;Z%I/@GQ_#X=\+:5HNGZEK>K3W5GHK:-?11:
MGJ][KDSZO<JX6]CL["&2,QVJ"OV*^'_@'PS\,/!GA#X>^"["/1_!_@3PMX>\
M%^%M%@51;Z5X;\*Z)IOA[0-.APH.S3])TJUM(SQE%P1A5"]G10 5X_\ '[X&
M?#O]I?X*_%3X _%C1H]>^''QA\!>*/AWXQTMD@,DFB^*M*N-+GO=/EN(+A;#
M7-):=-5\/:O#']KT76K2RU2Q>*[M89%]@HH _&3_ ()N_P#!#3]D/_@EG\2O
M''Q,_9B\3?&V/4/B+X3B\(>+- \:^/4\0^%]3LK74(-3T^_DTE-)L4.K:;=Q
M2M97SO)+!'=W<*8BGD5N"_;2_P"#>K]A3]NW]JV]_;%^,^H?&6U^+%]'\.XI
M8?!_C>VT3POCX9:=INF>&W.COHMXSR?9M+@6[9KH^:2_EB+//[L44 4=,L(=
M*TZPTRW:1H-.LK6QA>9@\SQ6D$<$;RN H>5DC#2/@;G); SBKU%% %>2W,BE
M?-D0$L1Y>U>&4 *2!\R@@L0?OYPV0*^'?B=_P3W_ &:_BI^U+\#?VS];\(#3
MOVD/@-J%\_AKXE: EGIVL^(?#>J:->:-<^"O&QCMB/$GAVUCO9;G0UO%?4/#
M[K]FTN]M[!GM3]U4U5"C [^O/M0!^-?_  4G_P""&O[&_P#P5/\ B)\/OB=^
MTOJ/Q7M_$GPS\!WOP\\-#X?^+X/#%@NAWWB&\\1RO>6C:5?K<W8NKZ:W\PLJ
M-:[%DC9T5Q^HGP7^$7A7X$_"?X:?!OP4^I/X2^%7@OP_X$\,OJ]V;[5'T7PW
MI<&DV!U&]V1_:[DV\"M+(8U4RDLJ*  /4J* "JMS")O*R3A)-W! YVE1R>1P
M3T(//6K503-LV$_=R0?Q( ]_RJHJ\DM_+Y,F<N6,I<[I\L9-S5M(V?-NFM8N
M47IM)^J^'/VO?V%_@%^U[#\*+SXO>%XKWQ;\#OB1X4^*OPL\?:7!8V?C;P=X
MD\$:K:ZW:1Z3K36DMPNAZJ8S8:SH;EM.N;6=IEMTNXXIE_E9_:(^(E[^S!_P
M60\<?%FZ,I_X1C]H6S\9ZO#"&68^#O%::1=:W!%+NC!74O".JW4$-MN9)2ES
M)(KMFO[=)2LT<8/#,94SCL1*@4G/ 9O+4G&< #OFOXZ/^"^'P;G\&?M6>$OB
MJMKMT'XR?#_1FFO5REN/%O@)IO"^H1.RH-MQ;Z-?^&Y'RY:7^TC)C$#)7)FU
MJ>&C5BN6M2KT+R2U<.:7-J[K72_NZ]T['][_ +.6ODN+\;>+_"[B%82IDGC%
MX/\ %_AWC*>,J2A'$5:F.P^-E1P_+4I3GCZF">%>%A3JPJ)9<YQ4I*<I?U>>
M/_AA\*?V@?AQ?^!/B7X+\$_%;X8^+[2TNKSPGXWT/2_$_A77--NX_M&G7+V&
MI07%J0;2X%Q87=OY=Q"S)+;S12!6K^:KX^?\&?'_  3)^+OBO5_%WPZ\8?M
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MWU/A%*4TI2CR2:NXWOR]$K^B7W^04444AA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
&444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm248202d5_424b5sp3img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm248202d5_424b5sp3img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !X -X# 2(  A$! Q$!_\0
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M4?\ KK!_Z,6J_P  O^280_\ 7W-_,58^.O\ R2G4?^NL'_HQ:@^ 7_),(?\
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&%%% '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
